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ABSTRACT 
 
 
 Lyme Disease, caused by the spirochete Borrelia burgdorferi, is the most 
common vector-borne disease in the United States and Europe. If left untreated, it can 
lead to permanent damage to the nervous and musculoskeletal systems. In some cases, 
patients that receive the recommended antibiotic therapy develop a debilitating health 
condition associated with substantial health care costs. Despite current preventive 
measures, the incidence and the geographic distribution of Lyme Disease continues to 
increase. Recent estimates from CDC suggest that the true number of cases of Lyme 
Disease in the US is approximately 300,000 per year. Yet, there is currently no vaccine 
available for human use, and thus novel strategies to diminish the risk of human exposure 
to Borrelia burgdorferi are of utmost importance. In an effort to address this need, we 
developed and tested an array of oral vaccine candidates based on recombinant E. coli 
that express B. burgdorferi’s OspC type K, OspB, BBK32, and Ixodes scapularis Salp15 
and Salp25. Only oral immunization with live E. coli expressing OspC K induced 
systemic immune responses characterized by high levels of OspC K-specific IgG 
antibodies in sera as well as IgA antibodies in mucosal secretions, obtained from C3H-
HeN mice. Vaccine efficacy studies demonstrated that OspC K-vaccinated mice were not 
protected from infection when challenge was performed via the natural route of disease 
transmission using ticks infected with multiple strains of B. burgdorferi, as assessed by 
the presence of antibodies to B. burgdorferi coupled with positive cultures and positive q-
PCR results from bladder, heart and ear. Most importantly, we have shown that 
antibodies specific to OspC type K do not protect mice from infection when the 
homologous type of B. burgdorferi is transmitted via ticks harboring also other types of 
OspCs. Our findings are both critical and relevant, and should be considered in future 
studies involving the design and development of OspC-based vaccines against Lyme 
Disease. 
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CHAPTER 1.    INTRODUCTION 
 
 
Literature Review 
 
 
Lyme Disease: a public health concern 
 
Lyme Disease, caused by the spirochete Borrelia burgdorferi sensu lato, is the 
most common vector-borne illness in the world [1]. In Europe and Asia, B. garinii, B. 
afzelii and B. burgdorferi sensu stricto (hereafter referred to as B. burgdorferi) are 
responsible for most human cases, whereas in North America B. burgdorferi is the sole 
cause of Lyme Disease [2, 3]. There is no vaccine available for humans. Despite current 
preventive measures, the number of reported cases in the US and elsewhere continues to 
increase. Newly revised estimates from The Centers for Disease Control and Prevention 
(CDC) suggest that the true number of cases of Lyme Disease in the US is approximately 
300,000 per year [4], 10 times higher than the official number reported by the CDC in 
2013 (Figure 1-1) [5], making Lyme Disease the third most common Notifiable Disease 
in the nation [6]. Of all Lyme Disease cases reported to the CDC in 2013, 95% were from 
14 states located in the Northeastern (New York, Connecticut, Pennsylvania, 
Massachusetts, Maine, Vermont, New Hampshire and Rhode Island), Mid-Atlantic (New 
Jersey, Maryland, Delaware and Virginia) and North Central (Wisconsin and Minnesota) 
regions (Figure 1-2) [5], where vector Ixodes scapularis ticks pose a high risk of 
infection [7]. Lyme Disease is endemic in North America, and its incidence is age-
related. Children are the most affected (Figure 1-3), probably because of their increased 
exposure to ticks [5]. Prompt diagnosis and treatment is critical to prevent disease 
progression. Except for the classic Erythema migrans (EM), the clinical manifestations of 
early Lyme Disease are not specific [8]. Thus, patients that do not develop EM are at risk 
for misdiagnosis and, consequently, for disease progression. If left untreated, patients can 
develop serious neurologic, cardiac and rheumatic manifestations weeks or months after 
infection [9]. Despite receiving the recommended antibiotic therapy, some Lyme Disease 
patients develop Post-treatment Lyme Disease Syndrome (PTLDS) [10-13], a debilitating 
condition that significantly impairs their life functioning [11]. Lyme Disease is associated 
with significant health care costs. Assuming that 300,000 cases occur annually [4], the 
total direct medical costs attributable to this disease could be approximately $890 million 
per year [14]. Predicted climate changes will likely promote and accelerate the expansion 
of I. scapularis to new geographic regions [15, 16], spreading the disease to areas that 
were previously non-endemic. As a result of northward expansion of I. scapularis Lyme 
Disease in now emerging in Canada and in some northern U.S. states [17-19].  
 
In summary, the new disease estimates have peaked at unprecedented figures and 
Lyme Disease is now reaching epidemic proportions greater than ever anticipated, with 
annual cases estimated to be 6 times greater than the 50,000 new HIV infections in the 
U.S. [1, 20]. Lyme Disease represents a growing health care and economic problem that 
has defied our attempts to control it. Alternative preventive measures to counteract this 
emergent epidemic are urgently needed.   
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Figure 1-1. Number of reported cases of Lyme Disease in the United States, from 
1995 to 2013. 
 
During 1995 to 2013, the annual confirmed case counts increased approximately 3-fold 
from 11,700 in 1995 to about 30,000 in 2013. CDC currently estimates that the true 
number is 10 times greater than the number of confirmed cases reported in 2013 [4].  
* National surveillance case definition revised in 2008 to include probable cases. 
Reprinted with permission from CDC, Reported Cases of Lyme Disease by Year, United 
States, 1995-2013 [5].  
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Figure 1-2. Geographic distribution of confirmed Lyme Disease cases in the 
United States in 2013.  
 
In 2013, 14 states (Connecticut, Delaware, Maine, Massachusetts, Maryland, Minnesota, 
New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, 
Virginia, and Wisconsin) accounted for 95% of confirmed US cases. One dot placed 
randomly within county of patient residence for each confirmed case. Reprinted with 
permission from CDC, Reported cases of Lyme Disease, United States, 2013 [21]. 
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Figure 1-3. Number of confirmed cases of Lyme Disease by age and sex in the 
United States, from 2001 to 2010.  
 
Incidence of Lyme Disease is higher in children, particularly in boys between 5 and 9 
years old. Reprinted with permission from CDC, Confirmed Lyme Disease cases by age 
and sex, United States, 2001-2010 [22]. 
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The discovery of Lyme Disease and its causative spirochete 
 
Lyme Disease was clinically described first by Dr. Alan Steere and colleagues in 
1977. It was reported as an “epidemic form of arthritis” in the small town of Lyme, 
Connecticut. At that time, based on the seasonal occurrence of the symptoms (in the 
summer and early fall) along with a tight geographic clustering of disease cases in rural 
areas, it was suggested that transmission might occur via an arthropod vector [23]. A 
significant breakthrough occurred in 1982 when Dr. Willy Burgdorfer and coworkers 
discovered that Ixodes ticks collected in a Lyme Disease endemic area carried a 
spirochete, which was proposed by the authors to be the etiologic agent of Lyme Disease 
[24]. This spirochete was subsequently named Borrelia burgdorferi in recognition of Dr. 
Burgdorfer’s discovery.  
 
More than three decades since the discovery of B. burgdorferi, there has been a 
remarkable accumulation of knowledge on the genetics, molecular biology, host and 
vector interactions of this pathogen. It is now understood that the ability of the spirochete 
to adapt and survive in two different environments, the tick (vector) and the vertebrate 
(host), is largely based on changes in B. burgdorferi gene expression. This topic has been 
elegantly reviewed elsewhere [25-27].  
 
Despite significant advances, our understanding of how B. burgdorferi 
coordinates changes in its gene expression, transcriptome, protein function, metabolism 
and cellular architecture during the transition between the tick and the mammalian host 
remains insufficient. In particular, the mechanisms by which I. scapularis promotes 
spirochetal ability to evade the host defenses need far more scrutiny.  
 
 
The enzootic cycle of B. burgdorferi 
 
In North America, the vast majority of Lyme Disease infections are acquired 
through the bites of the blacklegged or deer tick, I. scapularis, that carry B. burgdorferi 
[3]. The life cycle of the spirochete is depicted in Figure 1-4 and generally lasts 2 years. 
I. scapularis, the vector of B. burgdorferi, undergo a three-stage life cycle: larvae, 
nymph, and adult. Ticks take only one blood meal per each developmental stage. The 
cycle of B. burgdorferi transmission starts when uninfected ticks feed on reservoir hosts 
that are already infected with the spirochete. Ticks may become infected at any stage of 
their life (larvae, nymph or adult). Once acquired by the vector, B. burgdorferi is able to 
persist in the gut lumen through the next developmental stage, surviving within unfed or 
intermoult ticks. In the early summer, when larvae hatch from eggs they are non-infected 
with B. burgdorferi as there is no transovarial transmission [25, 28, 29]. Larvae can feed 
on a variety of reservoir hosts usually the white-footed mouse, Peromyscus leucopus, the 
natural reservoir for B. burgdorferi, but also on other small mammals or birds. 
Uninfected larval ticks may feed on infected reservoir hosts and acquire B. burgdorferi. 
Upon blood meal, larval ticks over winter and, in the following spring, moult into the 
next stage: nymphs. Infected nymphs represent the highest risk for humans and they feed 
on a similar range of hosts to larvae. Upon feeding, nymphs moult into the adult stage, in  
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Figure 1-4. The enzootic cycle of B. burgdorferi.  
 
Two-year life cycle of I. scapularis ticks, the vector of B. burgdorferi. Ticks undergo a 
three-stage life cycle- larvae, nymph and adult- with one blood meal per stage. In the 
summer, non-infected larvae hatch from the eggs. Unfed larval ticks may feed on a small 
mammal or bird infected with B. burgdorferi and become infected. Fed larvae survive the 
winter; they moult and emerge the following spring as infected nymphs. Nymphs are 
responsible for the vast majority of spirochete transmission to humans. Upon feeding, 
nymphs moult to become adults in the fall. During the winter, adult ticks mate, usually on 
large animals such as deer and feed on them. Fed female ticks lay eggs in the following 
spring, and the life cycle begins again. Reprinted with permission from CDC, The 
lifecycle of blacklegged ticks [28].  
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the fall. During the winter, adult ticks mate and feed on larger animals, preferably the 
deer, which are incompetent hosts for B. burgdorferi. After mating, female adult ticks lay 
eggs the following spring and, hence, the enzootic cycle begins again [8, 25]. Unlike 
reservoir hosts, humans are incidental or dead-end hosts. Yet, all three stages of I. 
scapularis can feed on humans [25]. Spirochaetes are deposited into the skin, at the site 
of the tick bite. A tick feeding period of at least 53 hours is usually needed for 
transmission of B. burgdorferi to occur [30]. Once in the dermis, B. burgdorferi can then 
disseminate to several internal organs, including the joints, heart and nervous system, and 
cause severe manifestations. 
 
 
Clinical manifestations of Lyme Disease 
 
The clinical manifestations of Lyme Disease varies depending on the stage of the 
illness and are classified into early localized disease (stage 1), early disseminated disease 
(stage 2), and late disease (stage 3) (Table 1-1) [8, 10, 13].  
 
Erythema migrans (EM) is the clinical hallmark of the early localized stage. By 
its clinical definition, a primary EM is “a round or oval expanding erythematous skin 
lesion that develops at the site of deposition of B. burgdorferi by an Ixodes species tick” 
[13], usually within 7 to 14 days (can range 3-30 days) after the bite. EM can gradually 
expand over time and reach up to 12 inches across, and as it enlarges, parts of the center 
of the rash may clear, resulting in a “bull's-eye” appearance. EM is found in about 70-
80% of patients with objective evidence of infection with B. burgdorferi. It is rarely 
symptomatic but might be pruritic and feel warm [10, 13, 31]. In the United States, 80% 
of patients with EM may experience simultaneous nonspecific systemic symptoms. Most 
frequently, they include malaise, headache, fever and chills, and myalgias and arthralgias 
whereas nausea, anorexia, dizziness, and difficulty concentrating are less common [31]. 
 
Multiple EM is the most common manifestation of the early disseminated stage 
and may develop days to weeks post tick bite after B burgdorferi spreads through the 
blood from the tick bite site to other areas of skin [10, 31]. Other manifestations of this 
stage include neurological symptoms (neuroborreliosis) such as loss of muscle tone on 
one or both sides of the face (facial or Bell's palsy), meningitis and radiculoneuritis as 
well as cardiac complications (Lyme carditis), most commonly manifested as 
atrioventricular block [8-10]. 
 
In the United States, arthritis is the most common manifestation of the late stage, 
and it affects one-third of the Lyme Disease patients [32]. Lyme arthritis occurs months 
to years after the initial tick bite and it causes intermittent or persistent attacks of swelling 
and pain in the large joints, especially the knee [10, 32]. Development of Lyme arthritis is 
associated with infection with B. burgdorferi OspC type A strain, which causes 
disseminated infection in humans [33], and is responsible for approximately 40% of the 
infections in the northeastern U.S. [32]. Although uncommon in children, encephalitis, 
encephalopathy, and polyneuropathy are also associated with late Lyme Disease [8]. 
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Table 1-1. Clinical manifestations of patients with Lyme Disease. 
 
Disease Stage Time Post-Tick Bite Clinical Manifestations 
 
Early localized 
 
 
3-30 days 
 
Erythema migrans 
Early disseminated 
 
Days to weeks Multiple erythema migrans 
Bell’s palsy 
Meningitis 
Carditis 
Late 
 
Months to years Arthritis 
Encephalitis 
Other neurological complications 
 
 
Sources: Murray TS, Shapiro ED, Lyme Disease. Clin Lab med., 2010. 30(1): p. 311-328. 
and Centers for Disease Control and Prevention, Signs and Symptoms of Lyme Disease 
2015 [8, 10]. 
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Diagnosis of Lyme Disease 
 
 According to the CDC, the diagnosis of Lyme Disease is based on signs and 
symptoms such as the typical EM, facial palsy, or arthritis, and a history of possible 
exposure to infected blacklegged ticks [34]. For serodiagnosis, the CDC recommends a 
two-tier test approach using an Enzyme-Linked Immunosorbent Assay (ELISA) or 
Immunofluorescent Assay (IFA) followed by a Western blot (Figure 1-5). The first test  
(ELISA or an IFA) allows for quantification of antibodies against B. burgdorferi in the 
sera and, thus, is more sensitive. Samples negative by ELISA or IFA do not need to be 
tested further. In contrast, if the first test is positive or indeterminate (equivocal), a 
second step should be performed to confirm the results. The second step uses a Western 
Blot (WB) assay, which is more specific than the first step tests. If the WB is performed 
during the first 30 days of disease onset (early LD), both IgM and IgG should be 
assessed. A positive IgM test result alone is not recommended for use in determining 
active disease in individuals with illness greater than 30 days of duration given the 
likelihood of a false-positive result. If the WB is performed after 30 days of disease onset 
(early LD), only IgG should be assessed [35]. In regard to test interpretation, for results to 
be considered positive, IgM blots are required to have at least two of the following three 
bands: 23 kDa (OspC), 39 kDa (BmpA), and 41 kDa (Fla). In case of IgG blots, a result is 
considered positive if at least five of the following ten bands are present: 18 kDa, 23 kDa 
(OspC), 28 kDa, 30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45 kDa, 58 kDa, 66 kDa, and 93 
kDa [36]. CDC does not recommend testing blood by WB without first testing it by 
ELISA or IFA [35]. Laboratory tests should be interpreted in the context of the clinical 
evaluation and the likelihood that the patient has Lyme Disease. 
 
Although the sensitivity of a serodiagnosis assay likely increases with the 
duration of the infection, the ability to detect infection during the early phase of the 
disease is poor given its dependence on antibody production [37]. The two-tiered testing 
has a high specificity (99-99.5%) and sensitivity (100%) at later stages of Lyme Disease, 
whereas it shows low sensitivity (about 35%) in patients with early-stage disease [38, 
39]. Another shortcoming of the current serologic assays is their inability in distinguish 
between active and past infection, and patients remain seropositive for years, despite 
absence of active infection [37]. 
 
Current antibody-based assays are the only type of diagnostic testing for Lyme 
Disease approved by the US Food and Drug Administration. Therefore, providing this 
remains unchanged, prompt recognition of the disease will be limited. If not diagnosed in 
a timely manner, disease will progress and patients may suffer seriously debilitating 
complications, which are more difficult to treat [13]. Strategies such as early diagnosis, 
appropriate treatment, and preventive measures are imperative to counteract sequelae 
associated with disease progression. 
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Figure 1-5. Current CDC recommendations on serologic diagnosis of Lyme 
Disease: 2-tier algorithm. 
 
The CDC currently recommends a two-tier testing for the serodiagnosis of Lyme Disease 
as follows: the first required test is the Enzyme-Linked Immunosorbent Assay (EIA or 
ELISA) or the Immunofluorescence Assay (IFA). In a scenario where the first step is 
negative, no further testing is recommended. If the first test is positive or equivocal, the 
second test should be performed to confirm the results. The second test uses a Western 
Blot (WB) assay to detect IgGs if the patient has had symptoms for more than 30 days. 
Results are considered positive only if the ELISA/IFA and the WB are both positive. The 
IgM should not be screened if the patient has been ill for more than 30 days. Reprinted 
with permission from CDC, Two-Tiered testing for Lyme Disease [35]. 
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Treatment of Lyme Disease 
 
  The recommended treatment of Lyme Disease is published in detail in the 
literature [13]. It primarily involves antibiotic therapy and is based in guidelines 
developed by the Infectious Diseases Society of America. The following is a brief 
summary of their recommendations: 1) In the absence of specific neurologic 
manifestations, patients with early localized or early disseminated Lyme Disease 
associated with EM should receive oral doxycycline, amoxicillin or cefuroxime axetil for 
14 days; 2) In the presence of acute neurologic manifestations such as meningitis or 
radiculopathy, patients with early disseminated Lyme Disease should receive intravenous 
ceftriaxone (for adults) or parenteral ceftriaxone or cefotaxime?(for children); 3) Adult 
patients with arthritis and without clinical evidence of neurologic disease should receive 
oral doxycycline, amoxicillin, or cefuroxime axetil for 28 days; 4) Adult patients with 
arthritis and objective evidence of neurologic disease should receive parenteral therapy 
with intravenous ceftriaxone for 2–4 weeks [13].  
 
Although Lyme Disease is treated successfully with antibiotics in the majority of 
cases [13, 40], approximately 10-20% of the patients that receive an adequate course of 
antibiotic therapy may experience PTLDS, a set of symptoms including muscle and joint 
pains, cognitive difficulties, sleep disturbances or fatigue, that can last for years [10, 41]. 
Prolonged antibiotic therapy has failed in improving PTLDS symptoms and currently 
there is no Food and Drug Administration treatment approved for this condition [42]. 
Furthermore, joint inflammation may persist in a minority of patients for months or 
several years, despite receiving repeated courses of antibiotic therapy for late Lyme 
arthritis. This is termed Antibiotic-Refractory Lyme Arthritis [32]. 
 
 
B. burgdorferi  
 
 Biology. B. burgdorferi belongs to the eubacterial phylum Spirochaetes, in 
particular to the family Spirochaetaceae. Members of this phylum are identified by their 
distinct morphology that includes a wavelike body, a flexible cell wall, and a periplasmic 
flagella surrounded by an outer and inner membrane [43]. Similarly to Gram-negative 
bacteria, B. burgdorferi also contains an outer and an inner membrane. Yet, the 
spirochete exhibits a very distinct cellular organization and membrane composition. 
Unique features of its outer cell membrane include the lack of lipopolysaccharide, the 
presence of low density transmembrane proteins, and an extraordinary abundance of 
surface exposed lipoproteins [25, 27]. 
 
This extracellular organism is 10-30 µm long and 0.2-0.25 µm wide and replicates 
slowly as it divides every 8-12 h during log-phase growth. To be grown in the laboratory, 
the bacterium requires special media, Barbour-Stoenner-Kelly (BSK-H), and grows best 
at temperatures 30°C-34°C in microaerophilic conditions [44]. 
 
 Genome.  A B. burgdorferi genome was sequenced in 1997 by Fraser and 
colleagues [45]. It includes a linear chromosome of approximately 1 Mb in size and 
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extrachromosomal DNA elements that total about 600 kb, which contain twelve linear 
and nine circular plasmids [45, 46]. One of the most remarkable features of B. 
burgdorferi is a nearly complete absence of biosynthetic pathways. The spirochete is an 
auxotroph for all amino acids, nucleotides, enzyme cofactors and fatty acids. The 
metabolic capacity of B. burgdorferi is extremely limited as it lacks the genes encoding 
proteins of the tricarboxylic acid cycle or oxidative phosphorylation. Instead, the 
bacterium obtains energy from the fermentation of sugars to lactic acid via the Embden–
Meyerhof pathway. Genome sequence analysis found that while the chromosome is fairly 
conserved and carries the majority of housekeeping genes, several plasmid genes exhibit 
much greater variability in content and encode for most of the outer-surface lipoproteins, 
many of which are potentially involved in infectivity and virulence [25, 45, 46].  
 
 Lipoproteins.  B. burgdorferi is maintained in nature by alternating infections in 
tick and mammalian hosts, which demands spirochetal survival in two contrasting 
environments. To ensure success during its complex enzootic life cycle, the bacterium 
needs to sense the environmental cues and, accordingly, orchestrate the expression of 
fundamental genes [25]. The plasticity displayed in some of the spirochete's outer surface 
proteins (Osps) seems to be indicative of adaptations as the spirochete selectively 
expresses certain proteins that are essential for a specific stage of its life cycle [47]. 
Among Osps, lipoproteins play a pivotal role in persistence and survival of B. 
burgdorferi in the tick–host cycle. For instance, B. burgdorferi expresses outer surface 
protein A (OspA) but not OspC when residing in the midgut of unfed ticks [48, 49]. At 
this stage, the spirochete upregulates OspA, which binds to the tick receptor for OspA 
(TROSPA), enabling Borrelia to persist inside of ticks [50]. In contrast, when an infected 
tick starts feeding, Borrelia downregulates OspA and upregulates OspC [48, 49]. The 
spirochete then migrates towards the tick salivary glands, from where is transmitted to the 
host. Although the requirement of OspC for Borrelia migration from the tick midgut to 
the salivary gland remains debatable [30, 51-53], it is widely accepted that OspC is a B. 
burgdorferi virulence factor that is essential to establish host infection [51, 52]. OspC is a 
22 kDa B. burgdorferi lipoprotein that is encoded by circular plasmid 26 [47]. Analyses 
of OspC sequences have described 25 OspC phyletic types that are differentiated by letter 
designation (from A to U) [54, 55]. Sequence analysis of North American isolates of B. 
burgdorferi revealed that the amino acid sequences within an OspC type are more than 
99% identical, whereas a lower homology exists, approximately 80% on average, 
between different types of OspC [55]. Although OspC has been the focus of intense 
research, its function in early infection is not fully understood, neither is the mechanism 
by which its diversity is selectively maintained. 
 
 OspB is a 34 kDa surface-exposed lipoprotein encoded on B. burgdorferi linear 
plasmid 54. The OspB gene is highly conserved among B. burgdorferi isolates in the 
United States and exhibits high similarity in terms of protein sequence (about 50% 
homology) and structure to OspA [45, 47, 56]. The presence of OspB on the surface of B. 
burgdorferi within unfed ticks but not on fed ticks [57], and its similarity to OspA led to 
speculation that OspB could play an important role in the persistence of B. burgdorferi 
within unfed ticks. Indeed, OspB was shown not only to specifically bind to a protein or 
protein complex within the tick gut [58] but also to be essential for spirochetal adhesion 
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and survival within the tick midgut [56]. The mechanism by which B. burgdorferi OspB 
interacts with ticks and promotes survival remains to be explored. 
 
 BBK32 is a 47 kDa surface-exposed lipoprotein encoded on B. burgdorferi linear 
plasmid 36. It is upregulated during tick feeding and mammalian infection, and is 
involved in the attachment of spirochetes to the extracellular matrix by binding to host 
fibronectin and glycosaminoglycans (GAGs) [47, 59, 60]. B. burgdorferi mutants lacking 
BBK32 are significantly impaired in infecting mice, when compared with the parental 
wild-type strain [61]. In another study, BBK32-mediated fibronectin and GAG binding 
initiated the interactions between the spirochete and the host microvasculature, which led 
investigators to hypothesize that BBK32 may be needed for B. burgdorferi escape from 
the bloodstream, and thus spirochete dissemination [62]. More recently, a report using 
bioluminescent imaging of B. burgdorferi in vivo showed that BBK32 is required for 
optimal infectivity, particularly, when the infection progresses from colonization to the 
dissemination phase [63]. In addition, BBK32 contributes to spirochetal colonization of 
the joints, and this was exclusively dependent on its GAG-binding activity [64]. Taken 
together, these findings suggest that BBK32 is important for the spirochete pathogenicity 
during the early stages of infection. 
 
 
Vaccines as a strategy to prevent Lyme Disease 
 
Multiple efforts to prevent Lyme Disease using several measures have been 
enforced within communities [65]. However, clearly, they have not been sufficient as the 
number of disease cases continues to rise [4]. Moreover, a human vaccine against Lyme 
Disease was licensed by the FDA, but it was withdrawn from the market a few years 
later, for multiple reasons [66, 67]. Therefore, a powerful strategy to effectively reduce B. 
burgdorferi prevalence remains to be developed and is of utmost importance. Vaccination 
against infection is a highly effective means to control the spread of disease in a 
population and it remains a promising strategy to prevent Lyme Disease [68]. Currently, 
there is no vaccine available to immunize humans. Novel vaccination approaches should 
be explored with the ultimate goal of minimizing the risk of human exposure to Lyme 
Disease, and thus, detain this epidemic.  
 
As described earlier, outer surface lipoproteins play an important role in 
virulence, host–pathogen interactions, and in maintaining the enzootic cycle of B. 
burgdorferi. Furthermore, antibodies directed at lipoproteins have been shown to protect 
animals [69-72] and humans [73] from infection with B. burgdorferi. In addition, several 
canine lipoprotein-based vaccines are currently commercially available [66]. Hence, 
lipoproteins have been considered important vaccine candidates to prevent Lyme 
Disease.  
 
 OspC.  OspC has been intensively investigated as a candidate Lyme Disease 
vaccinogen as a DNA vaccine [74-76] and a recombinant protein-based vaccine [69, 77-
80]. A disadvantage of the OspC vaccine is the heterogeneity of OspC proteins among 
Borrelia strains. Studies have been shown that OspC immunization elicits protective 
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immunity against challenge with homologous B. burgdorferi strains [69, 70, 74, 77, 79] 
but fails to protect from infection with heterologous B. burgdorferi strains [76, 78]. Yet, 
other authors have demonstrated that OspC antibodies fail to confer homologous 
protection against some B. burgdorferi strains [80]. One hypothesis that can be put forth 
to explain these inconsistencies regarding the potential of OspC as a vaccinogen relates to 
the fact that different studies used different strains of B. burgdorferi, different doses, and 
different routes to assess for vaccine efficacy. Nevertheless, OspC has been most 
promising amongst other vaccine candidates against Lyme Disease, and is included in the 
formulation of an OspA-based canine vaccine (Novibac® Lyme), presently being 
commercialized. OspC is currently considered a promising candidate for a second-
generation vaccine [66].  
 
Given the heterogeneity of OspC proteins, some authors have been working 
towards the development of a polyvalent chimeric OspC vaccine. Although claiming that 
these constructs can afford a broader protection [81, 82], these findings are built on 
speculation because their vaccine efficacy studies were solely based on in vitro 
experiments, and thus are distant from representing the natural context of B. burgdorferi 
transmission.  
 
 OspC type K is one of the four types (A, B, I and K) that causes disseminated 
Lyme Disease in humans [33], and has been shown to be highly distributed amongst 
important host species for B. burgdorferi [83]. Combined with another type, OspC type K 
was able to detect anti-OspC antibodies present in 96% of the Lyme Disease patients 
infected with several types of B. burgdorferi in the United States [84]. 
 OspB. Because OspB is a tick-specific protein that is upregulated within unfed 
ticks and repressed during tick feeding at the time of spirochete deposition in the host 
[57], the great majority of Lyme Disease patients, naturally infected mice and mice 
experimentally infected via tick bite do not produce antibodies to OspB [85, 86]. Yet, due 
to its important role in colonizing the tick gut, OspB has been considered an important 
candidate for a transmission-blocking vaccine [56, 58]. In fact, complement-independent 
IgG antibodies to OspB were able to disrupt the outer membrane of B. burgdorferi, 
resulting in osmotic lysis of the spirochete in vitro [87]. In another study, nonbactericidal 
antibodies to OspB significantly inhibited the attachment of B. burgdorferi to the tick gut 
in vivo, and effectively prevented I. scapularis colonization by spirochetes [58]. 
 
 BBK32.  Humoral responses to BBK32 are found in the sera of B. burgdorferi-
infected dogs [88], mice and humans [71, 86, 89] and can influence the progression of the 
disease. For instance, higher levels of antibodies to BBK32 during early infection have 
been associated with shorter and less severe Lyme arthritis [89]. Active and passive 
immunization with BBK32 partially protected mice against B. burgdorferi infection via 
needle challenge [71, 72]. Furthermore, antibodies against BBK32 have been shown to 
reduce spirochete transmission from the tick vector during feeding [72]. 
In addition to vaccination strategies based on B. burgdorferi antigens such as 
lipoproteins, the use of tick proteins as vaccine candidates has also been considered a 
promising measure to block tick–host–pathogen interactions and thus, transmission. Tick 
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immunity has been described and it happens when, upon repeated exposure to ticks, the 
host becomes resistant to subsequent tick bites [67, 90, 91]. Targeting an arthropod 
protein that is either required for pathogen acquisition by the vector or for transmission 
from the tick to the mammalian host is an attractive approach to interfere with the 
pathogen cycle. 
 
 Salp15.  Tick salivary proteins that interact with B. burgdorferi are considered 
important targets for a vaccine against Lyme Disease [67]. Salp15 is a 15 kDa I. 
scapularis salivary protein that exhibits immunosuppressive properties, as it inhibits 
CD4+ T-cell activation, and thus facilitates the survival of spirochetes within the infected 
host [92]. In addition, Salp15 is able to bind to B. burgdorferi OspC and protect the 
spirochete from innate and adaptive immune responses, promoting Borrelia transmission 
from the tick to the host [93]. Antibodies to Salp15 have been shown to neutralize the 
antigen-associated immunosuppressive effect, to enhance pathogen clearance, and to 
partially protect mice against B. burgdorferi via tick challenge [91]. 
 Salp25.  Salp25D (hereafter referred to as Salp25) is a 25 kDa I. scapularis 
salivary protein that functions as a potent antioxidant [94]. It plays an important role in B. 
burgdorferi acquisition by the tick during feeding given that it detoxifies reactive oxygen 
species produced by neutrophils in the host, promoting spirochete survival during its 
transition from the mammalian host to the arthropod vector. Ticks that fed on mice 
immunized with Salp25 were significantly impaired in acquiring spirochetes, when 
compared with ticks that fed on the control group [95]. 
 
 
Mouse model of Lyme Disease 
 
One important landmark in the study of Lyme Disease was the development of 
animal models of infection. Mice are the natural reservoirs for B. burgdorferi. Although 
in nature, wild mice infected with the spirochete show no sign of disease, they develop a 
serological response to B. burgdorferi proteins [86] and become persistently infected 
[96]. Furthermore, specific inbred strains of the laboratory mouse Mus musculus infected 
with B. burgdorferi were found to exhibit features similar to those of human Lyme 
Disease. In particular, C3H/HeN mice develop a multi-systemic infection with 
reproducible arthritis and carditis, and are now a well-established model for Lyme 
Disease [25, 97-99]. Experimentally, mice can be infected with B. burgdorferi by needle 
inoculation or tick feeding [43], upon which the spirochete establishes a localized 
infection at the entry site and then quickly disseminates via the bloodstream to various 
tissues, including ear, joints, heart and bladder [98-100]. 
 
 
Scope and Objectives of Dissertation  
 
Despite current preventive measures, the incidence and the geographic 
distribution of Lyme Disease continues to increase [4, 16]. Lyme Disease has become a 
serious and expensive public health problem, and has now reached epidemic proportions 
[1, 14]. Yet, there is no vaccine available to protect humans from this illness, and thus 
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novel vaccine strategies shall be developed. Reservoir-targeted vaccines delivered via the 
oral route are a well-established strategy to reduce B. burgdorferi prevalence and, 
consequently, to diminish the risk of human exposure to Lyme Disease [100-102]. In an 
effort to integrate this knowledge and building up on it, our laboratory took an innovative 
approach and proposed to deliver promising vaccine antigens either from B. burgdorferi 
or from its vector, I. scapularis, via the oral route. We selected OspC type K, OspB and 
BBK32 from B. burgdorferi based on evidence that these proteins induced significant 
IgG immune responses when administered via a parenteral route [58, 69, 71, 72, 74, 79, 
87]. In addition, we elected two salivary gland proteins from I. scapularis -Salp15 and 
Salp25-, based on previous observations that they stand out as candidates for a vector-
targeted vaccine [67, 91, 95]. We rationalized that Salp15 and Salp25 vector targeted 
vaccines would improve on current reservoir-targeted vaccines formulations. 
 
Oral immunization has several advantages over routes of parenteral 
immunization. It obviates the need for sterile needles and syringes, poses less risk of 
disease-transmission, is easy to administer and to scale up, cost-effective, and can induce 
local and systemic immunity [103]. Orally delivered vaccines are currently licensed and 
have been shown to protect against viral and bacterial pathogens [104], including 
spirochetal infections [105]. In addition to the development of oral vaccines against 
Lyme Disease, projects in our laboratory are focused on the development of oral vaccines 
against other bacterial diseases such as Melioidosis (see supplemental data “Development 
of Oral Vaccines against Melioidosis”) and Leptospirosis (see supplemental data 
“Development of Oral Vaccines against Leptospirosis and Design of a Mouse Model of 
Acute Infection with Leptospira interrogans”), in which ingestion is one of the most 
important routes of infection [106-109]. Furthermore, we have previously shown that 
immunized mice were protected against infection with Leptospira interrogans [110] and 
B. burgdorferi [100-102], when the immunogens were delivered orally via recombinant 
E. coli. 
 
Our oral vaccine technology consisted of recombinant live E. coli expressing the 
leader sequence of B. burgdorferi OspA lipoprotein fused to the N-terminus of each 
candidate immunogen (OspC K, OspB, BBK32, Salp15 or Salp25). The leader peptide of 
OspA contains a tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) lipid moiety, the substrate 
for OspA lipidation, which has been associated with adjuvant activity and shown to be 
essential for the ability of B. burgdorferi lipoproteins to generate a strong humoral 
immune response after vaccination [111-113]. In a previous study, where we investigated 
the effect of the lipid modification of the leader peptide OspA in the localization of the 
antigen in live oral delivery vehicles, we showed that the lipidation of the leader peptide 
of OspA targeted the protein through the membrane and it accumulated in the cell wall. 
In contrast, mutation of the lipidation site generated a nonlipidated version of OspA that 
was localized mostly in the cell membrane [114]. We next applied this platform 
technology and developed Lactobacillus-based oral vaccines for plague [115] and E. coli-
based oral vaccines for Leptospirosis [110] where we were able to target the immunogens 
for translocation across the bacterial cytoplasmic membrane to the cell envelope as a 
consequence of lipid modification of the leader peptide OspA. The same rationale was 
applied to this work. By fusing the leader peptide of OspA to the N-terminus of each 
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candidate immunogen, we aimed to target them across the cytoplasmic membrane to the 
cell envelope of E. coli. 
 
Here, we proposed to develop and test five (OspC type K, OspB, BBK32, Salp15 
and Salp25) oral vaccine candidates against Lyme Disease. The ultimate goal of our 
studies was to determine whether these candidates delivered via the oral route could 
induce a humoral immune response that would protect mice against infection delivered 
by ticks infected with heterologous strains of B. burgdorferi.  
 
Amongst all the vaccine candidates that we have selected for this study, OspC is 
considered the most promising and thus, the most studied in the literature. Although wild 
ticks transmit a heterologous mixture of B. burgdorferi OspC strains to their host [55, 83, 
116, 117], the literature lacks studies where the efficacy of OspC-based vaccines is 
assessed under conditions that fully mimic the natural route of B. burgdorferi infection. 
Yet, OspC is currently considered as one of the most promising second-generation Lyme 
Disease vaccine candidates. While this is the result of studies that failed to test OspC 
vaccines with the natural route of B. burgdorferi infection, it is essential that future 
studies learn from prior mistakes and investigate the potential of OspC-based vaccines in 
the natural context of the Lyme spirochete transmission. Aim 2 of this work intends to 
address this limitation, as we propose to test our most promising vaccine candidate 
against challenge with ticks infected with multiple strains of B. burgdorferi.  
 
 
Specific aim 1 
 
To develop oral vaccine constructs and understand the vaccine-induced humoral 
immune response. To achieve this aim we proposed to: 1) clone B. burgdorferi outer 
surface proteins (OspC K, OspB and BBK32) and I. scapularis proteins (Salp15 and 
Salp25) in E. coli: 2) deliver the recombinant E. coli to mice via the oral route and 3) 
assess antigen-specific total IgGs, IgG1, IgG2a in sera and IgA in mucosa. 
 
 
Specific aim 2 
 
To test the vaccine efficacy of our most promising oral vaccine candidate. To 
achieve this aim we proposed to immunize mice with our most promising oral vaccine 
candidate and challenge them with ticks carrying multiple strains of B. burgdorferi. 
Protection from infection was determined by: 1) Assessing the production of antibodies 
to B. burgdorferi proteins; and 2) Presence of B. burgdorferi along with spirochetal DNA 
quantification in target tissues and in nymphs that feed on immunized mice. 
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
B. burgdorferi Strains and Cultivation 
 
 Low-passage B. burgdorferi strain BL204 (an OspC type K strain, kindly 
provided by Dr. Ira Schwartz, NYMC) and B. burgdorferi strain B31MI (an OspC type A 
strain) were used. A culture containing multiple strains of B. burgdorferi (MS) was also 
used in our studies. This culture was originally isolated from the heart of Peromyscus 
leucopus infected with field caught ticks from endemic areas for Lyme Disease (New 
York State). B. burgdorferi strains B31MI and BL204 were used as positive controls for 
ospC type A and ospC type K, respectively, in the PCR studies. Both cultures of B. 
burgdorferi strain BL204 and B. burgdorferi multiple strains were used to generate flat 
nymphs infected with B. burgdorferi OspC type K strain or with multiple strains of B. 
burgdorferi, respectively. All B. burgdorferi used in this study were cultured in Barbour-
Stoenner-Kelly (BSK-H) medium (New York Medical College, NY) with an antibiotic 
mixture for Borrelia (Sigma-Aldrich, Saint Louis, MO), and grown at 34° C until the 
cells reached the mid-log-phase as previously described [118]. The number of spirochetes 
was determined using dark field microscopy (AxioImager, Zeiss, Germany) and q-PCR.  
 
 
Oral Vaccine Candidates Construction 
 
 To construct our oral vaccine candidates (Table 2-1), the genes OspC type K 
(OspC K), OspB and BBK32 from Borrelia burgdorferi sensu stricto, and Salp15 and 
Salp25 from Ixodes scapularis were synthesized and cloned by Blue Heron (Blue Heron 
Biotechnology, Inc., WA, USA) into the Nde I-Bam HI restriction sites of pET9c using 
codons optimized for expression in E. coli, and fused to the nucleotide sequence 
encoding the leader peptide of outer surface protein A (OspA) from B. burgdorferi. DNA 
constructs were then transformed into the E. coli strain BL21 (DE3) pLysS. The parental 
E. coli strain transformed with the empty plasmid was used as a control construct (ctrl).  
 
 
Protein Purification 
 
 To produce recombinant proteins to use in ELISA and Western blot assays, the 
genes OspC K, OspB, BBK32, Salp15 and Salp25 were synthesized and cloned by Blue 
Heron into the XhoI and BamHI restriction sites of pET28a, downstream of the 6xHis 
peptide tag. DNA constructs were then transformed into the E. coli strain BL21 (DE3) 
pLysS. Recombinant E. coli clones in pET28a vector expressing either the following 
proteins, OspC K, OspB, BBK32, Salp15 and Salp25 were grown in Tryptone Broth 
Yeast (TBY) medium supplemented with 50 μg/ml Kanamycin at 37°C, shaking at 225 
rpm, until it reached an OD600 of 0.8. The expression of 6xHis -OspC K, -OspB, -BBK32, 
-Salp15 and -Salp25 recombinant proteins was induced by adding 1 mM of isopropyl-b-
D-thiogalactopyranoside (IPTG, Gold Biotechnology, St. Louis, MO) followed by 
incubation at 37°C for 3 hrs. The cells were harvested by centrifugation at 4000 x g for  
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Table 2-1. List of oral vaccine constructs. 
 
Vaccine 
Construct 
Sequence Product 
Length 
(bp) 
 
OspC K 
 
CATATGAAAAAATACCTGCTGGGTATCGGTCTGATCC
TGGCGCTGATCGCGTGCAAACAGAACGTTTCTTGCAA
CAACTCTGGTAAAGACGGTAACACCTCTGCGAACTCT
GCGGACGAATCTGTTAAAGGTCCGAACCTGACCGAAA
TCTCTAAAAAAATCACCGAATCTAACGCGGTTGTTCTG
GCGGTTAAAGAAATCGAAACCCTGCTGGCGTCTATCG
ACGAACTGGCGACCAAAGCGATCGGTAAAAAAATCC
AGCAGAACGGTGGTCTGGCGGTTGAAGCGGGTCACAA
CGGTACCCTGCTGGCGGGTGCGTACACCATCTCTAAA
CTGATCACCCAGAAACTGGACGGTCTGAAAAACTCTG
AAAAACTGAAAGAAAAAATCGAAAACGCGAAAAAAT
GCTCTGAAGACTTCACCAAAAAACTGGAAGGTGAACA
CGCGCAGCTGGGTATCGAAAACGTTACCGACGAAAAC
GCGAAAAAAGCGATCCTGATCACCGACGCGGCGAAA
GACAAAGGTGCGGCGGAACTGGAAAAACTGTTCAAA
GCGGTTGAAAACCTGGCGAAAGCGGCGAAAGAAATG
CTGGCGAACTCTGTTAAAGAACTGACCTCTCCGATCGT
TGCGGAATCTCCGAAAAAACCGTAAGGATCC 
 
657 
 
OspB 
 
CATATGAAAAAATACCTGCTGGGTATCGGTCTGATCC
TGGCGCTGATCGCGTGCAAACAGAACGTTTCTTGCGC
GCAGAAAGGTGCGGAATCTATCGGTTCTCAGAAAGAA
AACGACCTGAACCTGGAAGACTCTTCTAAAAAATCTC
ACCAGAACGCGAAACAGGACCTGCCGGCGGTTACCGA
AGACTCTGTTTCTCTGTTCAACGGTAACAAAATCTTCG
TTTCTAAAGAAAAAAACTCTTCTGGTAAATACGACCT
GCGTGCGACCATCGACCAGGTTGAACTGAAAGGTACC
TCTGACAAAAACAACGGTTCTGGTACCCTGGAAGGTT
CTAAACCGGACAAATCTAAAGTTAAACTGACCGTTTC
TGCGGACCTGAACACCGTTACCCTGGAAGCGTTCGAC
GCGTCTAACCAGAAAATCTCTTCTAAAGTTACCAAAA
AACAGGGTTCTATCACCGAAGAAACCCTGAAAGCGAA
CAAACTGGACTCTAAAAAACTGACCCGTTCTAACGGT
ACCACCCTGGAATACTCTCAGATCACCGACGCGGACA
ACGCGACCAAAGCGGTTGAAACCCTGAAAAACTCTAT
CAAACTGGAAGGTTCTCTGGTTGGTGGTAAAACCACC
GTTGAAATCAAAGAAGGTACCGTTACCCTGAAACGTG
AAATCGAAAAAGACGGTAAAGTTAAAGTTTTCCTGAA
CGACACCGCGGGTTCTAACAAAAAAACCGGTAAATGG
GAAGACTCTACCTCTACCCTGACCATCTCTGCGGACTC 
 
921 
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Table 2-1. (Continued). 
 
Vaccine 
Construct 
Sequence Product 
Length 
(bp) 
 
 
 
TAAAAAAACCAAAGACCTGGTTTTCCTGACCGACGGT
ACCATCACCGTTCAGCAGTACAACACCGCGGGTACCT
CTCTGGAAGGTTCTGCGTCTGAAATCAAAAACCTGTC
TGAACTGAAAAACGCGCTGAAATAAGGATCC 
 
 
 
BBK32 
 
CATATGAAAAAATACCTGCTGGGTATCGGTCTGATCC
TGGCGCTGATCGCGTGCAAACAGAACGTTTCTAAAAA
AGTTAAATCTAAATACCTGGCGCTGGGTCTGCTGTTCG
GTTTCATCTCTTGCGACCTGTTCATCCGTTACGAAATG
AAAGAAGAATCTCCGGGTCTGTTCGACAAAGGTAACT
CTATCCTGGAAACCTCTGAAGAATCTATCAAAAAACC
GATGAACAAAAAAGGTAAAGGTAAAATCGCGCGTAA
AAAAGGTAAATCTAAAGTTTCTCGTAAAGAACCGTAC
ATCCACTCTCTGAAACGTGACTCTGCGAACAAATCTA
ACTTCCTGCAGAAAAACGTTATCCTGGAAGAAGAATC
TCTGAAAACCGAACTGCTGAAAGAACAGTCTGAAACC
CGTAAAGAAAAAATCCAGAAACAGCAGGACGAATAC
AAAGGTATGACCCAGGGTTCTCTGAACTCTCTGTCTG
GTGAATCTGGTGAACTGGAAGAACCGATCGAATCTAA
CGAAATCGACCTGACCATCGACTCTGACCTGCGTCCG
AAATCTTCTCTGCAGGGTATCGCGGGTTCTAACTCTAT
CTCTTACACCGACGAAATCGAAGAAGAAGACTACGAC
CAGTACTACCTGGACGAATACGACGAAGAAGACGAA
GAAGAAATCCGTCTGTCTAACCGTTACCAGTCTTACCT
GGAAGGTGTTAAATACAACGTTGACTCTGCGATCCAG
ACCATCACCAAAATCTACAACACCTACACCCTGTTCTC
TACCAAACTGACCCAGATGTACTCTACCCGTCTGGAC
AACTTCGCGAAAGCGAAAGCGAAAGAAGAAGCGGCG
AAATTCACCAAAGAAGACCTGGAAAAAAACTTCAAA
ACCCTGCTGAACTACATCCAGGTTTCTGTTAAAACCGC
GGCGAACTTCGTTTACATCAACGACACCCACGCGAAA
CGTAAACTGGAAAACATCGAAGCGGAAATCAAAACC
CTGATCGCGAAAATCAAAGAACAGTCTAACCTGTACG
AAGCGTACAAAGCGATCGTTACCTCTATCCTGCTGAT
GCGTGACTCTCTGAAAGAAGTTCAGGGTATCATCGAC
AAAAACGGTGTTTGGTACTAAGGATCC 
 
1137 
 
Salp15 
 
CATATGAAAAAATACCTGCTGGGTATCGGTCTGATCC
TGGCGCTGATCGCGTGCAAACAGAACGTTTCTGAATC 
 
483 
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Table 2-1. (Continued). 
 
Vaccine 
Construct 
Sequence Product 
Length 
(bp) 
 
 
 
TTTCGTTGCGATGAAAGTTGTTTGCATCCTGTTCCTGG
TTGGTGTTGTTGCGGCGAACGAATCTGGTCCGACCAA
AGCGGACGCGTCTACCGCGGACAAAGACACCAAAAA
AAACAACGTTCAGCTGCGTTTCCCGAACTACATCTCTA
ACCACCAGAAACTGGCGCTGAAACTGCTGAAAATCTG
CAAAGACTCTAAATCTTCTCACAACTCTCTGTCTTCTC
GTTCTTCTGACGTTATCAACGACAAATACGTTGACTTC
AAAAACTGCACCTTCCTGTGCAAACACGGTAACGACG
TTAACGTTACCCTGAACCTGCCGGAAGACACCCCGTG
CGGTCCGAACGGTCAGACCTGCGCGGAAAAAAACAA
ATGCGTTGGTCACATCCCGGGTTGCTAGTAAGGATCC 
 
 
 
Salp25 
 
CATATGAAAAAATACCTGCTGGGTATCGGTCTGATCC
TGGCGCTGATCGCGTGCAAACAGAACGTTTCTGGTCC
GCTGAACCTGGGTGACCCGTTCCCGAACTTCACCTGC
GACACCACCGAAGGTAAAATCGACTTCCACGAATGGC
TGGGTAACTCTTGGGGTATCCTGTTCTCTCACCCGGCG
GACTACACCCCGGTTTGCACCTCTGAACTGGCGCGTG
CGGCGCAGCTGCACCACGTTTTCCAGAAAAAAGGTGT
TAAACTGATCGCGCTGTCTTGCGACTCTGTTGAATCTC
ACCGTGGTTGGATCAAAGACATCAACGCGTTCGGTGA
ACTGCCGGACGGTCCGTTCCCGTACCCGATCATCGCG
GACGAAAAACGTGACATCGCGGTTAAACTGGGTATGC
TGGACCCGGTTGAAAAAGACAAAGAAGGTCTGCCGCT
GACCTGCCGTGCGGTTTTCATCATCGGTCCGGACAAA
AAAATGAAACTGTCTATGCTGTACCCGGCGACCACCG
GTCGTAACTTCGACGAAGTTCTGCGTGCGACCGACTC
TCTGCTGGTTACCGAAACCCGTAAAGTTGCGACCCCG
GCGGGTTGGCAGAAAGGTACCCCGTGCATGGTTCTGC
CGTCTGTTACCGAAGAAGAAATCCTGAAACTGTTCCC
GACCGGTATCAAACAGTACGAAGTTCCGTCTGGTAAA
AACTACCTGCGTACCACCATGGACTGAGGATCC 
 
 
738 
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10 min at 4°C. The pellet was isolated and subjected to cell wall lysis by the BugBuster 
Protein Extraction Reagent (Novagen, Madison, WI), and the protein extraction protocol 
was followed according to instructions provided by the manufacturer. The 6xHis-tagged 
proteins were purified using the Ni-NTA Purification System (Invitrogen, Carlsbad, CA) 
following instructions provided by the manufacturer. Protein concentration was 
determined by the Bradford protein assay (Bio-Rad, West Berkeley, CA), and samples 
were stored at -80°C until use. 
 
 
Oral Vaccine Preparation 
 
 Recombinant E. coli clones in pET9c vector expressing either the following 
proteins: OspC K, OspB, BBK32, Salp15 and Salp25, or E. coli carrying the empty 
vector (ctrl), were cultured in TBY supplemented with 50 μg/ml Kanamycin at 37°C, 
shaking at 225 rpm, to an OD600 of 0.8. Protein expression was induced with 1 mM of 
isopropyl-b-D-thiogalactopyranoside (IPTG, Gold Biotechnology, St. Louis, MO) 
followed by incubation at 37°C for 3 hrs. The cells were harvested by centrifugation at 
4000 x g for 10 min at 4°C and resuspended in 20% glycerol/phosphate buffered salt 
solution (PBS, Gibco, Grand Island, NY) in 1% of the initial volume. Next, serial 
dilutions of recombinant E. coli were performed and adjustments were made to reach 1 x 
109 cells per 400μl of oral vaccine. Cell suspensions in aliquots of 2 ml were frozen 
quickly in a dry ice bath and stored at -80°C until use. Protein expression was examined 
by Western blot using protein-specific mouse antiserum.  
 
 
E. coli Cell Fractionation 
 
 Recombinant E. coli clones in pET9c vector expressing either the following 
proteins: OspC K, OspB, BBK32, Salp15 and Salp25 were cultivated in TBY medium 
supplemented with 50 μg/ml Kanamycin at 37°C, 225 rpm. At an OD600 = 0.8, cells were 
induced with 1mM of isopropyl-b-D-thiogalactopyranoside (IPTG, Gold Biotechnology, 
St. Louis, MO) for 3 hrs and grown to an OD600 of ~1. The cells were harvested by 
centrifugation at 20,000 x g for 10 min at 4°C and were washed 3 times with ice-cold 
phosphate buffered salt solution (PBS, Gibco, Grand Island, NY). The pellet was 
resuspended in ice-cold PBS supplemented with protease inhibitor cocktail (complete 
EDTA-free, Roche Diagnostics GmBH, Germany) to an OD600 ~ 1. E. coli cells were 
disrupted with a French press (Thermo Electron Corporation, Milford, MA) and 
centrifuged at 20,000 x g for 10 min at 4°C to isolate the cytosol fraction (supernatant) 
from the cell envelope (pellet). The pellet was resuspended in 1ml of ice-cold PBS 2% 
Triton-X114 (Sigma Aldrich, St. Louis, MO) (v/v) and was incubated at 0°C for 1 h with 
frequent gentle agitation. Phase separation was performed by warming the suspension for 
30 min in a 37°C water-bath, followed by centrifugation at 13 000 x g for 15 min at 25 
°C. The aqueous and detergent phases were collected, separated from each other and 
were washed 3 times as previously described [119]. Briefly, the aqueous phase was 
washed by adding fresh 10% Triton X-114 to a final concentration of 2%. The aqueous 
phase was rewarmed for 30 min in a 37°C water-bath and centrifuged at 13 000 x g for 
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15 min at 25 °C. The detergent phase was washed by diluting it to 1 ml in ice-cold PBS 
followed by rewarming for 30 min in a 37°C water-bath and a centrifugation at 13 000 x 
g for 15 min at 25 °C. Total extract (TE), Supernatant (SN), Cell envelope (CE), Cell 
Envelope/ Detergent phase (CE/DET) and Cell Envelope / Aqueous phase (CE/AQ) were 
analyzed on a 10% denaturing polyacrylamide gel and electrotransferred to a 
polyvinylidene difluoride membrane (PVDF, Millipore, Billerica, MA) for analysis by 
Western blotting using antigen-specific- polyclonal mouse antibody (anti-OspC K,-OspB, 
-BBK32,-Salp15 and-Salp25). Protein was quantified by densitometry using Alpha 
Imager (Alpha Innotech, San Leandro, CA). Cell fractionation studies were performed in 
triplicates in independent experiments.  
 
 
Animals 
 
 Six-eight week old female C3H-HeN mice specific-pathogen-free (Charles River, 
Boston) were used. Mice were housed in the Nash Research Building, room B072, at the 
University of Tennessee Health Science Center (UTHSC), Memphis and acclimated to 
housing for at least seven days prior to studies.  Throughout the experiments, mice were 
provided food and water ad libitum. At the end point, animals were euthanized by carbon 
dioxide asphyxiation followed by physical euthanasia. At the time of termination, bladder 
and heart samples were collected, immediately weighed and individually processed for 
DNA extraction and culture under sterile ABSL-2 conditions. All the protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC), UTHSC. 
 
 
Antibody Production 
 
 Groups of female BALB/c mice (n=3/protein) were immunized by subcutaneous 
(SC) injection with 30 μg of one of the following 6xHis-tagged recombinant purified 
proteins: OspC K, OspB, BBK32, Salp15 or Salp25, adsorbed to aluminum hydroxide 
(Sigma Aldrich, St Louis, MO). Two and four weeks after immunization, mice were 
boosted with the same immunogenic preparation. Immune sera was collected, stored and 
was used to perform Western Blot assays for protein expression, lipidation and cell 
localization studies.  
 
 
Oral Immunization 
 
 Aliquots of recombinant live E. coli expressing either the following proteins, 
OspC K, OspB, BBK32, Salp15 and Salp25 were thawed at 4°C and 400μl, a total of 1 x 
109 cells, were placed in a ball-tipped syringe for oral gavage inoculation. Groups of 
female C3H/HeN mice were immunized by intragastric inoculation of induced 
recombinant E. coli or with an equivalent number of E. coli containing the pET9c empty 
vector as controls. Groups of mice received E. coli expressing OspC K (n=12), OspB 
(n=6), BBK32 (n=6), Salp15 (n=4) or Salp25 (n=4) and equal numbers of mice (n=12; 
n=6; n=6; n=4 and n=4) were used as controls groups for each antigen, respectively. Mice 
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were immunized using a protocol similar to that we previously described for OspA 
immunization [105]. Mice received the first immunization, twice daily, for ten days (days 
1-5 and 8-12), rested for two weeks, received the first boost for five days (days 29-33), 
rested for another week and then received a second boost for five days (days 43-47), and 
were allowed to rest. On day 73, mice were terminated or challenged with infected ticks. 
Oral immunization studies were performed in triplicates in independent experiments. 
 
 
Blood and Stool Collection, Vaginal (VAL) and Bronchoalveolar Lavage (BAL) 
 
 Blood collection: low amounts of mouse blood (up to 50μl) were obtained via tail 
nick on the following days: 0 (pre-immune), 28, 42, 73, 105, 135 and 170 after 
immunization. Stool collection, vaginal lavage (VAL) and bronchoalveolar lavage (BAL) 
were performed at day 73 after immunization started. Stool collection: a sample of the 
stool (~60mg) was collected and diluted in ELISA buffer. Vaginal Lavage (VAL): 1ml of 
ELISA buffer was flushed into the mouse vagina over a petri dish and the fluid was 
collected. Bronchoalveolar lavage (BAL): mice were euthanized and 1 ml of ELISA 
buffer was injected into the lungs with immediate aspiration. 
 
 
Production of Infected Ticks (Flat Nymphs) 
 
 We produced laboratory I. scapularis ticks (flat nymphs) infected with B. 
burgdorferi with the ultimate goal of infecting OspC type K- immunized mice by the 
natural route of B. burgdorferi transmission, i.e., via tick bite, to assess for vaccine 
efficacy. Serial dilutions of culture of B. burgdorferi strain BL204 (OspC type K) and a 
culture containing multiple strains of B. burgdorferi (MS) grown to mid-log-phase were 
analyzed by dark field microscopy. Cells were counted by averaging eight microscope 
fields and the number of spirochetes was further confirmed by q-PCR. 50μl of BSK-H 
media containing 1 x 10 4 B. burgdorferi multiple strains or 1 x 10 4 B. burgdorferi strain 
BL204 was injected via intradermal route, in the back of the neck of C3H/HeN mice 
(n=4/group), to produce flat nymphs infected with B. burgdorferi multiple strains or 
infected with B. burgdorferi OspC type K, respectively. 4 weeks later (day 28), infection 
in mice was assessed by seroconversion to B. burgdorferi antigens. Mice were bled and 
their serum was tested for the presence of IgG anti B. burgdorferi antigens via 
immunoblotting assay (Borrelia B31 ViraStripe IgG, Viramed Biotech AG, Planegg, 
Germany). Batches of clean flat larvae (purchased from Oklahoma State University) were 
placed in the back of the head of anesthetized mice that seroconverted. After 1h, mice 
were checked to ensure larval ticks were attached, caged individually and monitored 
three times a day for six-seven days. Larvae were allowed to feed to repletion and 
engorge on mice. Engorged larvae were collected as they naturally fell off, stored at room 
temperature in 95% humidity and allowed to moult and harden into nymphal ticks (flat 
nymphs). Upon successful moulting, which took approximately three months; ten percent 
of the pools of flat nymphs generated in our lab were tested by q-PCR targeting the flaB 
gene to determine the prevalence of infection. All larvae were derived from a single 
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cohort for the experiments described here. Tick production studies were performed in 
duplicates in independent experiments. 
 
 
Tick Challenge of Immunized Mice 
 
 All nymphal challenges described here were performed using flat nymphs 
infected with B. burgdorferi multiple strains, generated in our laboratory. Nymphal 
challenge was performed at day 73, by placing six flat nymphs infected with multiple 
strains of B. burgdorferi on the back of the head of individually caged OspC type K- 
immunized mice and respective controls, allowing them feed to repletion. Five to seven 
days later, nymphs that engorged after a blood meal (engorged nymphs) were collected 
after naturally falling off, counted, and a daily record was kept for each mouse and for 
each tick. Only mice where at least two fully fed nymphs were collected were included in 
the final readout. Hundred percent of the pools of engorged nymphs recovered after 
nymphal challenge, comprising nymphs that fed on OspC K-immunized mice or on 
control mice, were processed for DNA extraction and tested by q-PCR and PCR to assess 
for vaccine efficacy. Tick challenge studies were performed in duplicates in independent 
experiments. 
 
 
Collection of Bladder, Heart and Ear Samples 
 
 Ear biopsy samples were collected from mice eight weeks (day 135) after 
nymphal challenge as previously described [120]. Bladder and heart samples were 
collected from euthanized mice four weeks (day 105) and thirteen weeks (day 170) after 
nymphal challenge, and harvested under a laminar flow biosafety containment hood. 
Collected tissues were immediately sampled in half, weighed and individually cultured 
into BSK-H medium for six weeks. The other half of weighed tissues was immediately 
stored at -20°C for further PCR and q-PCR analysis. 
 
 
Indirect Enzyme-Linked Immunosorbent Assay (ELISA) 
 
 
Measurement of IgG and IgA antibodies to OspC K, OspB, BBK32, Salp15 and 
Salp25 proteins 
 
 Serum, BAL, VAL and stools from mice that were orally immunized with 
recombinant E. coli clones (OspC K, OspB, BBK32, Salp15 and Salp25) or orally 
inoculated with E. coli carrying the empty vector (ctrl) were tested by indirect ELISA for 
the presence of IgG or IgA to OspC K, OspB, BBK32, Salp15 and Salp25. Purified 
recombinant 6xHis-tagged proteins (OspC K, OspB, BBK32, Salp15 and Salp25) were 
coated overnight at 4°C (2μg/ml) in 100mM sodium carbonate (pH 9.7) on Nunc 
MaxiSorp flat-bottom ELISA plates (eBioscience, San Diego, CA). Following incubation 
time, plates were washed 3 times with PBS (Gibco, Grand Island, NY) containing 0.05% 
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Tween 20 and subsequently blocked with PBS containing 1% of bovine serum albumin 
(BSA, Sigma-Aldrich, St. Louis, MO) for 1h at room temperature. Serum, BAL, VAL or 
stools (1:100) were incubated for 2 hrs at room temperature. Plates were washed 3 times 
with PBS containing 0.05% Tween 20. Goat anti-mouse IgG (1:50,00), anti-mouse IgG1 
(1:50,000), anti-mouse IgG2a (1:50,000) or goat anti-mouse IgA (1:50,000) horseradish 
peroxidase-conjugated antibody (Jackson ImmunoResearch Laboratories, West Grove, 
PA) was incubated for 30 min at room temperature. Plates were washed 3 times and 
reactions were developed with SureBlue™ TMB Microwell Peroxidase Substrate (KPL, 
Gaithersburg, MD) and stopped with TMB Stop Solution (KPL, Gaithersburg, MD). 
Optical densities (OD) were measured at 450 nm by a Spectra MAX plus ELISA reader 
(Molecular Devices, Sunnyvale, CA). 
 
 
Measurement of total IgG antibodies to recombinant B. burgdorferi proteins  
 
 Serum from mice that were orally immunized with recombinant E. coli expressing 
OspC K or inoculated with E. coli carrying the empty vector (ctrl) was tested by ELISA 
for the presence of total IgG anti-B. burgdorferi proteins 4 weeks (day 105) after 
nymphal tick challenge to assess for vaccine efficacy. A cocktail of purified recombinant 
proteins from B. burgdorferi including p41, p100, BmpA, DbpA, DbpB, FlaB (ProSpec, 
East Brunswick, NJ), VlsE (My BioSource, San Diego, CA) and BBK07 (kindly 
provided by Utpal Pal, University of Maryland) were coated overnight at 4°C (2μg/ml) in 
100mM sodium carbonate (pH 9.7) on Nunc MaxiSorp flat-bottom ELISA plates 
(eBioscience, San Diego, CA). Indirect ELISA was performed under the same conditions 
described above; goat anti-mouse IgG (1:50,00) horseradish peroxidase-conjugated 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as 
secondary antibody. Optical densities (OD) were measured at 450 nm by a Spectra MAX 
plus ELISA reader (Molecular Devices, Sunnyvale, CA). 
 
 
Western Blot 
 
 
Detection of recombinant OspC K, OspB, BBK32, Salp15 and Salp25 proteins  
 
 Total extracts (TE), supernatant (SN), pellet (cell envelope), and the aqueous and 
detergent fractions of the cell envelope of E. coli expressing OspC K, OspB, BBK32, 
Salp15 and Salp25 were separated on a 10-12% denaturing polyacrylamide gel and 
electro transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, 
MA) by semi-dry transfer. After blocking overnight at 4˚C with 5% BSA (Sigma-
Aldrich, St. Louis, MO) in tris-buffered saline (Bio-Rad, West Berkeley, CA), 0.05% 
Tween-20 (TBST), samples were washed 3 times with 1% BSA in TBST and incubated 
for 1h at room temperature with specific mouse polyclonal antiserum (anti-OspC K, -
OspB, -BBK32, -Salp15 or -Salp25) using a 1:100 dilution. Samples were washed 3 
times and incubated for 30 min at room temperature with goat anti-mouse IgG (H+L) 
conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratories, West Grove, 
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PA) using a 1:1,000 dilution. Samples were washed 3 times and reaction was developed 
with BCIP/NBT Phosphatase Substrate (KPL, Gaithersburg, MD). Purified 6xHis-tagged 
recombinant proteins (rOspC K, rOspB, rBBK32, rSalp15 and rSalp25) were used as 
positive controls for protein identification purposes, during the characterization of protein 
expression of our oral vaccine constructs. 
 
 
Detection of total IgG antibodies to recombinant B. burgdorferi proteins  
 
 The immunoblot test Borrelia B31 ViraStripe IgG (Viramed Biotech AG, 
Planegg, Germany) was performed according to the manufacturer’s instructions and it 
was used to screen for anti-B. burgdorferi IgG antibodies in serum from OspC K-
vaccinated mice 4 weeks (day 105) after nymphal tick challenge. A pattern of at least 5 
out of 10 positive bands (18, 23, 28, 30, 39, 41, 45, 58, 66 and 93kDa) in control mice or 
a pattern of at least 5 out of 10 positive bands (18, 28, 30, 39, 41, 45, 58, 66 and 93kDa) 
in OspC K-vaccinated mice was considered evidence of infection, as per CDC 
recommendations [36].  
 
 
Culture of B. burgdorferi from Tissues and Dark Field Microscopy 
 
 Heart, bladder and ear biopsy tissues freshly collected from mice before (day 73) 
or after tick challenge (days 105, 135 and 170) were individually cultured in BSK-H 
medium (New York Medical College, NY) with an antibiotic mixture for Borrelia 
(Sigma-Aldrich, Saint Louis, MO) for up to 6 weeks at 34°C. Cultures were checked 
every week by dark field microscopy (AxioImager, Zeiss, Germany) for the presence of 
Borrelia burgdorferi. Cultures were deemed positive if Borrelia cells were observed in 
any field and negative if no Borrelia cells were observed in 10 fields. 
 
 
DNA Extraction and Preparation 
 
 DNA from B. burgdorferi cultures, flat and engorged nymphs, heart, bladder and 
ear collected from mice before (day 73) or after tick challenge (days 105, 135 and 170) 
was extracted with the DNeasy blood and tissue kit according to the manufacturer’s 
instructions (Qiagen, Valencia, CA). The extracted DNA was stored at -20°C until use. 
To monitor for contamination, negative controls were included in the DNA-extraction. 
As an additional measure to prevent contamination, DNA extractions were carried out in 
a separate laboratory from the PCR reaction preparations.  
 
 
Real Time Quantitative Polymerase Chain Reaction (q-PCR) 
 
 DNA extracted from flat nymphs, engorged nymphs, heart, bladder and ear was 
quantified for the copy numbers of flaB by qPCR to determine the number of B. 
burgdorferi in each sample. qPCR was performed in an StepOnePlus™ Real-Time PCR 
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System (Applied Biosystems, Foster City, CA) using two flaB-specific primers designed 
in our lab designated as flaB-587F (TCTTTTCTCTGGTGAGGGAGCT) and flaB-635R 
(AGAGGGTGTTCAACAGGAAGG). Genomic copy numbers were quantitated with a 
6-carboxy-fluorescein/ 6-carboxy-tetramethyl-rhodamine-labeled probe flaB-611 (6-
FAM-AAACTGCTCAGGCTGCACCGG–TAMRA). Reactions contained a final 
concentration of 0.3μM of each primer (Eurofins Scientific, Huntsville, AL), 0.2μM of 
the specific probe (Eurofins Scientific, Huntsville, AL), 10ul of Maxima Probe qPCR 
Master Mix (Thermo Fisher Scientific, Grand Island, NY), 2μl of DNA solution (≤ 500 
ng DNA) and nuclease-free water (Sigma-Aldrich, Saint Louis, MO) up to a total volume 
of 20μl. Reactions containing no DNA were also included as controls. The amplification 
protocol consisted of 10 min at 95ºC, followed by 40 cycles of amplification (95ºC for 15 
s and 60ºC for 1 min). The flaB copy number was determined essentially as described 
previously [121]. Briefly, standard curves relating the flaB copy number and spirochete 
number were generated using a dilution series (containing 1–106) of a titered culture of 
mid-log phase (5×10 7/ml) B. burgdorferi B31MI, as assayed by dark-field microscopy. 
The flaB copy number was confirmed by a PCR-based limited-dilution assay. DNA 
samples containing 1 –106 copies of flaB were included in each qPCR in order to 
generate a standard curve. Under these conditions, an assay sensitivity of 1 spirochete 
was achieved. A positive result was considered when one or more copies of flaB were 
detected. Amplification was performed using MicroAmp Fast Optical 96-Well Reaction 
Plate (Applied Biosystems, Foster City, CA). Two sets of 1 well were assigned as blanks 
and two sets of 6 wells were assigned as DNA standards for flaB. Blanks, standards and 
samples were amplified in duplicate wells. To avoid cross-contamination and sample 
carry-over, pre- and post-PCR sample processing and PCR amplification were performed 
in separate rooms and all fluid transfers were carried out with plugged pipette tips to 
eliminate aerosols. Each assay contained six negative controls containing no DNA and 
one sham extraction to assure no DNA contamination in the extraction reagents. These 
controls were randomly spaced among the experimental samples.  The mean DNA copy 
numbers of flaB of each DNA sample were calculated from duplicate wells. Number of 
B. burgdorferi was expressed as the average number of flaB DNA copies per mg or mm 
of tissue or per tick. 
 
 
Polymerase Chain Reaction (PCR) and Gel Electrophoresis 
 
 B. burgdorferi ospC, ospC type A and ospC type K were amplified from DNA 
extracted from B. burgdorferi cultures, flat, engorged nymphs, heart and bladder using 
primers designated as OspC, OspC type A and OspC type K, respectively, that were 
designed in our laboratory (Table 2-2). Reactions contained a final concentration of 
0.6μM (Borrelia cultures and tick samples) or 0.4μM (tissue samples) of each primer 
(Eurofins Scientific, Huntsville, AL), 10ul of AmpliTaq Gold® Fast PCR Master Mix 
(Applied Biosystems, Foster City, CA), 5 μl (Borrelia culture and tick samples) or 3μl 
(tissue samples) of DNA solution (≤ 0.2 μg DNA) and nuclease-free water up to a total 
volume of 20μl. Reactions containing no DNA were also included as controls. For DNA 
samples extracted from cultures of B. burgdorferi multiple strains and from flat and 
engorged nymphs, DNA fragments of the loci of interest were amplified by a nested PCR 
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Table 2-2. List of primers used for PCR.  
 
Name Forward 
 
Reverse 
 
Product 
Length 
(bp) 
Anneal. 
Temp. 
(°C) 
 
OspC 
 
 
GGAGGCACAAAT
TAATG 
 
GACTTTATTTTTCC
AGTTAC 
 
705 
 
47 
 
OspC type A 
 
 
CCGAAAATAATC
ACAATGGATC 
 
CCAAGTTCTTCAG 
CACC 
 
256 
 
51 
 
OspC type K 
 
 
GAAGCGGGGCA 
TAATGGAA 
 
CGCATGTTCTCCTT
CTAGT 
 
 
165 
 
51 
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procedure, comprising ospC amplification as the first reaction and ospC type A or ospC 
type K amplification as the second reaction. Here, the first round PCR product was used 
as template for the second round PCR. For DNA samples extracted from tissue samples 
(heart and bladder), DNA fragments of the loci of interest (ospC type A or ospC type K) 
were amplified by a single PCR reaction. B. burgdorferi strain B31MI (OspC type A 
strain), B. burgdorferi strain BL204 (OspC type K strain) and E.coli expressing OspC K 
(our OspC K vaccine construct) were used as positive controls for ospC type A and ospC 
type K, respectively. The amplification protocol of ospC consisted of 10 min at 95ºC, 
followed by 35 cycles of amplification (96ºC for 3s, 47ºC for 3s and 68 ºC for 15s). The 
amplification protocol of ospC type A and ospC type K consisted of 10 min at 95ºC, 
followed by 35 (for Borrelia culture samples) or 45 cycles (for nymphs and tissue 
samples) of amplification (96ºC for 3s, 51ºC for 3s and 68 ºC for 5s), and was performed 
in separate PCR reactions. In addition to standard laboratory measures to prevent 
contamination, negative controls at various stages of amplification were performed for 
each PCR reaction. After amplification, 10 μl of product were loaded on a 1% agarose gel 
to be separated by electrophoresis. The separated bands were visualized using ethidium 
bromide staining and were detected using an Alpha Image 2200 Multi-image light cabinet 
and alphaEase FC software (Alpha Innotech Corporation, San Leandro, CA). PCR 
products were further confirmed by sequencing (Genewiz, South Plainfield, NJ). In an 
effort to detect other types of ospC besides ospC type K, ospC type A was included in our 
studies. 
 
 
Statistical Analysis 
 
 Values were expressed as means ±SD. For comparison of means between two 
populations of unpaired data, unpaired student’s t-test was used. GraphPad Prism 5 
(GraphPad Software Inc., San Diego, CA) was used to perform all tests. Differences were 
considered significant at p <0.05. 
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CHAPTER 3.    RESULTS 
 
 
Construction of Recombinant E. coli Expressing OspC K, OspB, BBK32, Salp15 
and Salp25, and Localization and Lipidation of Target Proteins within the Cell 
 
 We cloned the outer surface protein C type K (OspC K), the outer surface protein 
B (OspB) and the fibronectin binding protein (BBK32) genes from B. burgdorferi sensu 
stricto as well as Salp15 and Salp25 from I. scapularis, downstream of the signal peptide 
of Borrelia burgdorferi outer surface protein A (OspA) into an E. coli expression 
plasmid. By doing so, we generated the oral vaccine constructs, described in  
Table 2-1, expressing recombinant immunogens anchored to the cell envelope of the 
bacteria via a lipidated moiety [115]. Total extracts (TE) of our five oral vaccine 
constructs (E. coli expressing OspC K, OspB, BBK32, Salp15 and Salp25) along with the 
respective purified proteins (rOspC K, rOspB, rBBK32, rSalp15 and rSalp25) used as 
positive controls, were analyzed by denaturing polyacrylamide gels and protein 
expression was confirmed by Western blot. All recombinant proteins migrated at the 
expected molecular weight: OspC K at 24 kDa (Figure 3-1A, top panel), OspB at 34 
kDa (Figure 3-1B, top panel), BBK32 at 42 kDa (Figure 3-1C, top panel), Salp15 at 18 
kDa (Figure 3-1D, top panel) and Salp25 at 27 kDa (Figure 3-1D, top panel) as 
identified by Western blot using monospecific polyclonal antibodies. We next evaluated 
the localization of the recombinant proteins within the cell envelope of E. coli by cell 
fractionation followed by Western Blot (Figure 3-1, top panels) and quantification by 
densitometry (Figure 3-1, bottom panels). Analysis of cytosol (SN) and cell envelope 
(CE) fractions revealed that OspC K (Figure 3-1A), OspB (Figure 3-1B), BBK32  
(Figure 3-1C), Salp15 (Figure 3-1D) and Salp25 (Figure 3-1E) are primarily (>60%) in 
the cell envelope (CE) fraction. When the CE fraction was further fractionated by Triton 
X-114 solubilization and phase partitioning, OspC K (Figure 3-1A), BBK32  
(Figure 3-1C) and Salp15 (Figure 3-1D) were found primarily (76.0%, 61.2% and 
82.9%, respectively) in the Triton X-114 hydrophobic, detergent phase (CE/DET) 
whereas OspB (Figure 3-1B) and Salp25 (Figure 3-1E) were found primarily (74.3% 
and 71.7%, respectively) in the aqueous phase of the cell envelope (CE/AQ).  
 
 
Serological Total IgG Antibody Response to Orally Delivered E. coli Expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 Antigens 
 
 We immunized C3H-HeN mice by oral gavage with live E. coli expressing OspC 
K, OspB, BBK32, Salp15 and Salp25. Control mice received live E. coli carrying the 
empty vector (Ctrl). Serum from immunized mice was analyzed by ELISA for the 
presence of antigen-specific total IgG antibodies (tIgG) on day 73, after immunization 
started (Figure 3-2). Oral immunization with OspC K (Figure 3-2A) induced significant 
levels of antigen-specific total IgG with a mean antibody level of OD450=1.108 (± 0.303 
SD) when compared to mean antibody levels of OD450=0.221 (± 0.127 SD) in controls, 
p<0.0001. In contrast, oral immunization with OspB (Figure 3-2B), BBK32  
(Figure 3-2C), Salp15 (Figure 3-2D) and Salp25 (Figure 3-2E) did not induce  
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Figure 3-1. Lipidation and localization of recombinant OspC K, OspB, BBK32, 
Salp15 and Salp25 in E. coli. 
 
E. coli expressing OspC K (A), OspB (B), BBK32 (C), Salp15 (D) and Salp25 (E) were 
disrupted with a French press. Total extracts (TE), supernatant (SN) and the pellet  
(CE = cell envelope) were collected. The cell envelope was then incubated with Triton X-
114 and partitioned into detergent (CE/DET) and aqueous (CE/AQ) phases. Fractions 
were analyzed on a 10-12% SDS PAGE and tested by Western blot with monospecific 
polyclonal mouse antibody (top panels). Protein in the supernatant, cell envelope, 
detergent phase and aqueous phase was quantified by densitometry using Alpha Imager 
(Alpha Innotech, San Leandro, CA) (bottom panels). Purified recombinant 6xHis-tagged 
proteins: rOspC K (A), rOspB (B), rBBK32 (C), rSalp15 (D) and rSalp25 (E) were used 
as positive controls and showed a relative molecular mass of 24, 34, 42, 18 and 27 kDa, 
respectively. 
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Figure 3-2. Serological total IgG antibody response to orally delivered E. coli 
expressing OspC K, OspB, BBK32, Salp15 and Salp25 antigens.  
 
C3H-HeN mice were immunized intragastrically with live recombinant E. coli expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 or inoculated intragastrically with live E. coli 
carrying the empty vector (Ctrl). C3H/OspC K n=12 and control n=12; C3H/OspB n=6 
and control n=6; C3H/BBK32 n=6 and control n=6; C3H/Salp15 n=4 and control n=4; 
C3H/Salp25 n=4 and control n=4. Serum samples were collected at day 73 and anti-OspC 
K (A), -OspB (B), -BBK32 (C), -Salp15 (D) and -Salp25 (E) total IgG was measured by 
ELISA and expressed as Optical Density at 450 nm (OD450). The average of triplicate 
readings per mouse/per group was determined and the error bar indicates standard 
deviation. Results are representative of one of three independent experiments. Asterisks 
indicate statistically significant differences, **** p<0.0001. 
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significant levels of antigen-specific total IgG when compared to the respective control 
groups, p>0.05. 
 
 
Subtyping of Total IgG Antibody Response to Orally Delivered E. coli Expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 Antigens 
 
 We next isotyped total IgGs into IgG1 and IgG2a subclasses in serum obtained 
from mice at day 73 (Figure 3-3), by ELISA. Mice orally immunized with live E. coli 
expressing OspC K (Figure 3-3A) developed significant OspC K-specific IgG1 levels 
with a mean antibody level of OD450=0.322 (± 0.171 SD) when compared to a mean 
antibody level of OD450=0.056 (± 0.026 SD) in controls, p<0.0001, as well as significant 
OspC K-specific IgG2a levels with a mean antibody level of OD450=0.375 (± 0.110 SD) 
when compared to a mean antibody level of OD450=0.116 (± 0.040 SD) in control group, 
p<0.0001. Differences between anti-OspC K IgG1 and anti-OspC K IgG2a were not 
significant, p=0.3820 (Figure 3-3A). Oral immunization with live E. coli expressing 
OspB (Figure 3-3B), BBK32 (Figure 3-3C), Salp15 (Figure 3-3D) and Salp25  
(Figure 3-3E) did not induce significant levels of antigen-specific IgG1 neither IgG2a 
when compared to respective control groups, p>0.05. 
 
 
Mucosal IgA Antibody Response to Orally Delivered E. coli Expressing OspC K, 
OspB, BBK32, Salp15 and Salp25 Antigens 
 
 We assessed local and distal mucosal immune responses induced by oral 
administration of live E. coli expressing OspC K, OspB, BBK32, Salp15 and Salp25 in 
C3H-HeN mice. We tested levels of antigen-specific IgA in stool (GUT, local), 
bronchoalveolar lavage (BAL, distal) and vaginal lavage (VAL, distal) at day 73, by 
ELISA (Figure 3-4). Mice immunized orally with OspC K (Figure 3-4A) produced 
significant levels of OspC K-specific IgA antibodies not only locally at the site of 
immunization (GUT), mean OD450=0.425 (± 0.175 SD) compared to 0.233 (± 0.094 SD) 
in the control, p=0.0030; but also at mucosal sites distal to the gut, such as the lung 
(BAL) with a mean OD450=0.163 (± 0.071 SD) compared to 0.062 (±0.008 SD) in the 
control, p=0.0004, and in the vagina (VAL) with a mean OD450=0.385 (± 0.289 SD) 
compared to 0.093 (± 0.044) in the control, p=0.0022. Mice immunized orally with OspB 
(Figure 3-4B) and BBK32 (Figure 3-4C) produced some levels of IgA detectable in 
VAL, but were not significant when compared to the control, p=0.0642 and p=0.1311, 
respectively. We were not able to detect IgA antibodies in GUT, BAL or VAL of mice 
immunized orally with E. coli expressing Salp15 (Figure 3-4D) or Salp25 (Figure 3-4E).  
 Our findings suggested that only mice immunized with E. coli expressing OspC K 
induced a significant systemic antibody immune response showed by the production of 
antigen-specific serological IgG (Figure 3-2) and mucosal IgA (Figure 3-4). Therefore, 
studies to determine vaccine efficacy were pursued following oral immunization with E. 
coli expressing OspC K. 
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Figure 3-3. Subtyping of total IgG antibody response to orally delivered E. coli 
expressing OspC K, OspB, BBK32, Salp15 and Salp25 antigens.  
 
C3H-HeN mice were immunized intragastrically with live recombinant E. coli expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 or inoculated intragastrically with E. coli 
carrying the empty vector (Ctrl). C3H/OspC K n=12 and control n=12; C3H/OspB n=6 
and control n=6; C3H/BBK32 n=6 and control n=6; C3H/Salp15 n=4 and control n=4; 
C3H/Salp25n=4 and control n=4. Serum samples were collected at day 73 and anti-OspC 
K (A), -OspB (B), -BBK32 (C), -Salp15 (D) and -Salp25 (E) IgG1 and IgG2a were 
measured by ELISA and expressed as Optical Density at 450 nm (OD450). The average of 
triplicate readings per mouse/per group was determined and the error bar indicates 
standard deviation. Results are representative of one of three independent experiments. 
Asterisks indicate statistically significant differences, **** p<0.0001. The letters “ns” 
indicate nonsignificance (p>0.05). 
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Figure 3-4. Mucosal IgA antibody response to orally delivered E. coli expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 antigens.  
 
C3H-HeN mice were immunized intragastrically with live recombinant E. coli expressing 
OspC K, OspB, BBK32, Salp15 and Salp25 or inoculated intragastrically with E. coli 
carrying the empty vector (Ctrl). C3H/OspC K n=12 and control n=12; C3H/OspB n=6 
and control n=6; C3H/BBK32 n=6; and control n=6; C3H/Salp15 n=4 and control n=3; 
C3H/Salp25 n=4 and control n=3. At day 73, stools (GUT), bronchoalveolar lavage 
(BAL) and vaginal lavage (VAL) were collected and anti-OspC K (A), -OspB (B), -
BBK32 (C), -Salp15 (D) and -Salp25 (E) IgA antibodies were measured by ELISA and 
expressed as Optical Density at 450 nm (OD450). The average of triplicate readings per 
mouse/per group was determined. Results are representative of one of three independent 
experiments. Asterisks indicate statistically significant differences. The number of 
asterisks indicates the significance level: ** p<0.01, *** p<0.001. The letters “ns” 
indicate nonsignificance (p>0.05). 
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Production of Flat Nymphs Infected with B. burgdorferi 
 
 To generate flat nymphs infected with multiple strains (MS) of B. burgdorferi or 
with B. burgdorferi OspC type K (OspC K) strain, mice (n=4/group) were inoculated 
intradermally with 1 x 104 of B. burgdorferi MS or of B. burgdorferi strain BL204, 
respectively. Four weeks (day 28) after inoculation, serum was collected and analyzed for 
the presence of total IgG anti-recombinant B. burgdorferi proteins by Western Blot. 
Seroconversion to borrelial antigens was used as a measure of infection. All mice 
inoculated either with B. burgdorferi MS (MS) or B. burgdorferi OspC K strain (OspC 
K) seroconverted as shown by the presence of 6 (six) positive bands at 66, 41, 39, 28, 23 
and 18 kDa or at 93, 66, 45, 41, 23 and 18 kDa, respectively (Figure 3-5A). Next, non-
infected larvae were placed on seroconverted mice and allowed to feed to repletion. Fed 
larvae were then collected and led to moult into flat nymphs. After moulting, the 
infection prevalence of flat nymphs was assessed by q-PCR targeting the flaB gene. Flat 
nymphs infected with multiple strains of B. burgdorferi (MS) exhibited an infection 
prevalence of approximately 83%, with an average number of 1 x 10 5 B. burgdorferi per 
nymph (n=18) (Figure 3-5B). Surprisingly, despite the fact that all mice inoculated 
intradermally with B. burgdorferi strain BL204 (OspC K) became infected  
(Figure 3-5A), we were not able to generate infected flat nymphs from larvae that fed on 
any of these mice, as shown by an infection prevalence of 0% from these nymphs 
(Figure 3-5B). A total of 20 flat nymphs (5 flat nymphs per each mouse infected with B. 
burgdorferi OspC type K strain) were screened and none of them were infected. These 
results were further confirmed by PCR results using primers to amplify ospC from B. 
burgdorferi, followed by gel electrophoresis. Studies to determine OspC K vaccine 
efficacy were then pursued using the flat nymphs infected with multiple strains of B. 
burgdorferi that we generated.  
 
 
Characterization of the Efficacy of an E. coli-based Oral Vaccine Expressing 
Lipidated OspC K Anchored to the Cell Envelope in Preventing Infection with 
Multiple Strains of B. burgdorferi 
 
 We determined the efficacy of an E. coli-based oral vaccine expressing lipidated 
OspC K anchored to the cell envelope in preventing infection with multiple strains of B. 
burgdorferi upon tick challenge. To perform tick challenge studies, we used our 
laboratory produced flat nymphs infected with multiple strains of B. burgdorferi, which 
had an infection prevalence of approximately 83% (Figure 3-5B). We placed six flat 
nymphs on each OspC K-immunized mice (n=12) and respective controls (n=12), using a 
total of 144 flat nymphs. 72-blinded selected nymphs were placed on immunized group 
while the other 72 nymphs were placed on control group. After tick challenge, we 
recovered 57 out of the 72 nymphs placed on the control group and 58 out of the 72 
nymphs placed on the immunized group, an average of nymphal recovery rate of 80% 
and 81%, respectively (Table 3-1).  
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Figure 3-5. Production of flat nymphs infected with B. burgdorferi. 
 
C3H-HeN mice (n=4/group) were inoculated intradermally with 1 x 104 of B. burgdorferi 
(Bb) multiple strains (MS) or with B. burgdorferi BL204, an OspC type K strain (OspC 
K). At day 28, once seroconversion was confirmed by Western blot (A), non-infected 
larvae were placed on mice infected either with MS of B. burgdorferi or with B. 
burgdorferi OspC K strain aiming to produce flat nymphs infected with MS of B. 
burgdorferi or with B. burgdorferi OspC K strain, respectively. Larvae were allowed to 
feed to repletion, collected and led to moult into flat nymphs. Flat nymphs were subjected 
to DNA extraction followed by q-PCR analysis to quantify the number of copies of B. 
burgdorferi flaB gene. Results are represented as the average of duplicate samples per 
tick and each dot represents the number of B. burgdorferi per flat nymph. Black dots 
depict the number of B. burgdorferi per flat nymphs generated from larvae that fed on 
mice infected with multiple strains of B. burgdorferi (MS). Open dots depict the number 
of B. burgdorferi per flat nymph generated from larvae that fed on mice infected with B. 
burgdorferi OspC type K (OspC K) (B). Infection was considered when five or more 
positive bands were present in the Western Blot. Each Western Blot stripe (n=8) 
represents one mouse (n=8) (A). Results are representative of one of two independent 
experiments. 
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Table 3-1. List of nymphal ticks placed and recovered per mouse. 
 
Controla 
Mouse ID 
No. Flat 
Nymphs 
Placed 
No. 
Engorged 
Nymphs 
Recovered 
Vaccb. 
Mouse 
ID 
No. Flat 
Nymphs 
Placed 
No. 
Engorged 
Nymphs 
Recovered 
 
1 
 
6 
 
6 
 
13 
 
6 
 
5 
2 6 5 14 6 4 
3 6 2 15 6 5 
4 6 6 16 6 6 
5 6 3 17 6 6 
6 6 2 18 6 4 
7 6 6 19 6 6 
8 6 4 20 6 2 
9 6 6 21 6 6 
10 6 6 22 6 5 
11 6 5 23 6 4 
12 6 6 24 6 5 
 
Total no. 
 
 
72 
 
57 
 
Total no. 
 
 
72 
 
58 
Average 
(%) 
100 80 Average 
(%) 
 
100 81 
 
a Control mice (n=12) were inoculated intragastrically with E. coli carrying the empty 
vector. 
b Vaccinated mice (n=12) were inoculated intragastrically with E. coli expressing OspC 
K. 
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Detection of B. burgdorferi and B. burgdorferi DNA as a measure of vaccine efficacy 
 
After nymphal challenge, spirochetal infection and dissemination to target tissues 
was determined by culture and q-PCR (Figure 3-6). Bladder, heart and ear samples were 
collected at specific time points after tick challenge as follows: four weeks (day 105), 
eight weeks (day 135) and thirteen weeks (day 170), placed in culture and checked for the 
presence of B. burgdorferi by dark field microcopy. In addition, we extracted DNA from 
these tissues and performed a q-PCR analysis targeting flaB to quantify the average 
number of B. burgdorferi. All mice orally immunized with OspC K had positive cultures 
of B. burgdorferi from bladder and heart at four (day 105) and at thirteen weeks (day 
170), confirmed by positive q-PCR with an average number of 2.5 x 102 B. burgdorferi 
per mg of bladder (Figure 3-6A) and 3.7 x 102 B. burgdorferi per mg of heart  
(Figure 3-6B) tissue. In addition, we detected positive cultures of B. burgdorferi from 
ears in ten out of twelve OspC K-immunized mice, 8 weeks (day 135) after challenge. 
These findings were further confirmed by positive q-PCR, with an average number of 8.3 
x 102 B. burgdorferi per mm of ear sample (Figure 3-6C). Although we could not detect 
flaB copies in ears from two OspC K-immunized mice neither from two control mice 
(Figure 3-6C), these four animals were infected with B. burgdorferi as shown by 
analysis of their bladders (Figure 3-6A) and hearts (Figure 3-6B). We found no 
significant differences in the numbers of B. burgdorferi per mg of bladder (Figure 3-6A), 
per mg of heart (Figure 3-6B), or per mm of ear tissue (Figure 3-6C) between control 
and OspC K-immunized mice groups, p>0.05.  
 
 
Seroconversion to B. burgdorferi proteins as a measure of vaccine efficacy 
 
 We also examined the spirochete specific antibody response. Four weeks after 
challenge (day 105), serum was collected and analyzed for the presence of total IgG anti-
recombinant B. burgdorferi proteins by ELISA (Figure 3-7A) and Western Blot  
(Figure 3-7B). Sera and tissues collected from mice before challenge (day 73) were also 
analyzed and used as negative control. As expected, tissue samples collected from 
immunized and control mice at day 73 resulted in negative q-PCR results and B. 
burgdorferi was not detected in cultures (Figure 3-7A). As expected, control mice 
showed significantly high levels of IgG antibodies to B. burgdorferi proteins after 
challenge (day 105), when compared to the levels before challenge (day 73), p<0.0001. 
Similarly, immunized mice showed significantly high levels of IgG antibodies to B. 
burgdorferi proteins at day 105, comparing with levels day 73, p<0.0001 (Figure 3-7A), 
and there were no differences in the IgG levels when compared to controls at day 105 
(p>0.05). ELISA results were further confirmed by Western Blot (Figure 3-7B). All 
OspC K-immunized mice developed antibodies to B. burgdorferi proteins after tick 
challenge (day 105) as shown by the presence of eight positive bands (18, 23, 28, 30, 39, 
41, 66 and 93kDa) in the Western Blot (Figure 3-7B). There were no significant 
differences between immunized and control mice, except that all immunized mice 
presented an additional positive band at 23 kDa, that corresponds to B. burgdorferi OspC 
antigen (Figure 3-7B). The appearance of this band was expected given that all  
immunized mice received an OspC-based vaccine and all of them developed specific 
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Figure 3-6. Quantification of B. burgdorferi in tissues from OspC K-immunized 
mice after tick challenge.  
 
C3H-HeN mice (n=12/group) were immunized intragastrically with E. coli expressing 
OspC K (OspC K) or inoculated intragastrically with E. coli carrying the empty vector 
(Ctrl) and then challenged with flat nymphs infected with multiple strains of B. 
burgdorferi. To quantify infection and to assess spirochetal dissemination to target 
tissues, bladder, heart were collected at 4 (day 105) and 13 weeks (day 170), and ear 
samples were collected at 8 weeks (day 135), after tick challenge. Tissues were cultured 
in BSK-H medium and analyzed by dark field microscopy, and subjected to DNA 
extraction followed by q-PCR analysis to quantify the number of copies of B. burgdorferi 
flaB. Results are represented as the average of duplicate samples per mouse and each dot 
represents the number of B. burgdorferi per mg of bladder (A), mg of heart (B) or per 
mm of ear (C) tissue. Results are representative of one of two independent experiments. 
The letters “ns” indicate nonsignificance (p>0.05). A negative result for Borrelia culture 
was considered when B. burgdorferi was absent in cultures of tissues analyzed by dark 
field microcopy. A positive culture result was considered when B. burgdorferi was 
present in cultures of tissues analyzed by dark field microcopy.  
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Figure 3-7. Serological total IgG antibody response to B. burgdorferi after tick 
challenge in OspC K-immunized mice. 
 
C3H-HeN mice (n=12/group) were immunized intragastrically with E. coli expressing 
OspC K (OspC K) or inoculated intragastrically with E. coli carrying the empty vector 
(Ctrl) and then challenged with flat nymphs infected with multiple strains of B. 
burgdorferi. To assess infection, serum samples were collected before (day 73) and after 
challenge (day 105) and analyzed by indirect ELISA (A) and Western blot (B) for the 
presence of total IgG anti-recombinant B. burgdorferi proteins. For ELISA, the results 
are expressed as Optical Density at 450 nm (OD450) and the average of triplicate samples 
per mouse was determined and plotted. Asterisks indicate statistically significant 
differences, **** p<0.0001. The letters “ns” indicate nonsignificance (p>0.05). A 
negative result was considered when tissue DNA samples were negative for flaB by q-
PCR analysis and when B. burgdorferi was absent from cultures of tissues analyzed by 
dark field microcopy. A positive B. burgdorferi result was considered when tissue DNA 
samples were positive (one copy or more) for flaB by q-PCR analysis and when B. 
burgdorferi was detected in cultures of tissues analyzed by dark field microcopy (A). For 
Western blot, each stripe represents one mouse (n=24). A pattern of at least 5 out of 10 
positive bands (18, 23 (OspC), 28, 30, 39, 41, 45, 58, 66 and 93kDa) in control mice and 
a pattern of at least 5 out of 10 positive bands (18, 28, 30, 39, 41, 45, 58, 66 and 93kDa) 
in OspC K-vaccinated mice were considered evidence of infection (B). Results are 
representative of one of two independent experiments.  
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anti-OspC (type K) total IgG antibodies, as described (Figure 3-2A). 
Next, we analyzed all the recovered engorged nymphs that fed on OspC K-
imunized mice (n=58) and on control mice (n=57), which we had previously collected 
(Table 3-1). All engorged nymphs (n=115) were subjected to DNA extraction followed 
by q-PCR analysis targeting flaB to quantify the average number of B. burgdorferi per 
engorged nymph. Our findings showed that engorged nymphs that fed on immunized 
mice had an average number of 5.2 x 105 B. burgdorferi, which was no different from the 
average number B. burgdorferi per engorged nymph that fed on the control group (5.2 x 
105), p>0.05 (Figure 3-8).  
 Taken together, our findings suggested that an OspC K-based vaccine does not 
protect from infection with B. burgdorferi via tick bite. Aiming to investigate whether an 
OspC K-based vaccine could, at least, afford OspC type-specific protection, we next 
evaluated if OspC K-immunized animals were protected from infection with B. 
burgdorferi OspC type K transmitted by tick bite carrying multiple strains of B. 
burgdorferi (Figure 3-9). In addition, we investigated the level of antibodies to OspC 
type K after tick challenge (Figure 3-10).  
 
 
Evaluation of OspC K Type-Specific Protection 
 
Spirochetal cultures, nymphs and tissues were analyzed for the presence of B. 
burgdorferi OspC, OspC type A and OspC type K strains by targeting ospC, ospC type A 
and ospC type K, respectively (Figure 3-9). The band at 705bp in lanes 5 to 10 represents 
the general OspC gene analyzed by nested PCR (lanes 6, 7, 8, 9 and 10) or by single PCR 
(lane 5). A culture of B. burgdorferi BL204 strain (Bb OspC K) and our OspC type K 
oral vaccine construct in E. coli (Ec OspC K) were used as positive controls for ospC 
type K. Amplification of ospC type K was confirmed by the band at 165 bp in lanes 2 and 
3, respectively. To identify additional types of ospC other than type K, we targeted ospC 
type A. A culture of B. burgdorferi B31MI strain (Bb OspC A) was used as positive 
control for ospC type A as indicated by the band at 256bp in lane 1. B. burgdorferi OspC 
type K strain was detected in the culture containing multiple strains of B. burgdorferi as 
well as in the flat nymphs that we produced from this culture, as confirmed by the band at 
165bp in lanes 7, 8 and 10, respectively. Similarly, B. burgdorferi OspC type K strain 
was detected in engorged nymphs that fed on OspC K-immunized mice (lane 12) and also 
in the heart (lane 14) and bladder (lane 16) from these mice, as shown by band at 165bp. 
Furthermore, ospC type A was present in the culture containing multiple strains of B. 
burgdorferi (lanes 6 and 8), in flat nymphs (lane 9), in engorged nymphs (lane 11), and in 
the heart (lane 13) and bladder (lane 15) from OspC-K immunized mice, as indicated by 
the band at 256bp. 
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Figure 3-8. Quantification of B. burgdorferi in engorged nymphs that fed on OspC 
K-immunized mice. 
 
C3H-HeN mice (n=12/group) were challenged with flat (unfed) nymphs (n=6/mouse) 
infected with multiple strains of B. burgdorferi (MS). A total of 144 flat nymphs 
(n=72/group of mice) were used to perform the challenge. Upon challenge, 57 engorged 
nymphs that fed on control mice (Ctrl) and 58 engorged nymphs that fed on OspC K-
immunized mice (OspC K) were recovered. All recovered engorged nymphs (n=115) 
were then subjected to DNA extraction followed by q-PCR analysis to quantify the 
number of copies of B. burgdorferi flaB gene. Results are represented as the average of 
duplicate samples per tick and each dot represents the number of B. burgdorferi per 
engorged nymph. Nymphs (n=57) that fed on control mice are represented as “Ctrl” and 
black dots depict the number of B. burgdorferi per engorged nymph that fed on control. 
Nymphs (n=58) that fed on OspC K-immunized mice are represented as “OspC K” and 
open dots depict the number of B. burgdorferi per engorged nymph that fed on 
immunized mice. The letters “ns” indicate nonsignificance (p>0.05). 
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Figure 3-9. Presence of B. burgdorferi OspC type K in engorged nymphs that fed 
on OspC K-immunized mice and in mouse tissues. 
 
1% agarose gel electrophoresis showing representative PCR products after ospC (705bp), 
ospC type A (256bp) and ospC type K (165bp) amplification. The first lane (L) shows 
100bp DNA marker. Lanes 1, 2 and 3 are positive controls. Lane 1: shows ospC type A in 
a culture of B. burgdorferi B31MI strain, an OspC type A strain culture (Bb OspC A); 
lane 2: shows ospC type K in B. burgdorferi BL204 strain culture, an OspC type K strain 
culture (Bb OspC K); lane 3: shows ospC type K in the oral vaccine construct, E. coli 
expressing OspC type K (Ec OspC K); lane 4: negative control (NC); lane 5: shows ospC 
in B. burgdorferi multiple strains culture (Bb MS); lane 6: shows ospC and ospC type A 
in B. burgdorferi multiple strains culture (Bb MS); lane 7: shows ospC and ospC type K 
in culture of B. burgdorferi multiple strains (Bb MS); lane 8: shows ospC type A and 
ospC type K in B. burgdorferi multiple strains culture (Bb MS); lane 9: shows ospC and 
ospC type A in flat nymphs produced from B. burgdorferi multiple strains culture; lane 
10: shows ospC and ospC type K in flat nymphs produced from B. burgdorferi multiple 
strains culture; lane 11: shows ospC type A in engorged nymph that fed on OspC K-
immunized mice; lane 12: shows ospC type K in engorged nymph that fed on OspC K-
immunized mice; lane 13: shows ospC type A in heart tissue from OspC K-immunized 
mice; lane 14: shows ospC type K in heart tissue from OspC K-immunized mice;  lane 
15: shows ospC type A in bladder tissue from OspC K-immunized mice; lane 16: shows 
ospC type K in bladder tissue from OspC K-immunized mice. 
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Figure 3-10. Serological total IgG response to OspC K from mice immunized orally 
with recombinant E. coli expressing OspC K before, during and after tick challenge. 
 
C3H-HeN mice (n=12) were immunized intragastrically with E. coli expressing OspC K and 
then challenged with flat nymphs infected with multiple strains of B. burgdorferi, at day 73. 
Serum samples were collected before immunization (day 0) and after immunization, 
including time points before (days 0, 28, 42 and 73) and after tick challenge (days 105, 135 
and 170). Serum samples were analyzed by ELISA for the presence of specific serological 
anti-OspC K total IgG antibodies (total IgG). The results are expressed as Optical Density at 
450 nm (OD450). The average of triplicate samples per mouse was determined and the error 
bar indicates standard deviation. Asterisks indicate statistically significant differences in 
total IgG levels in OspC K-immunized mice compared to the control group at the same 
time points. The number of asterisks indicates the significance level: *** p<0.001, **** 
p<0.0001. Results are representative of one of three independent experiments. 
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Serological Total IgG Antibody Response to OspC K in Mice Orally Immunized 
with E. coli Expressing OspC K before, during and after Tick Challenge 
 
We compared the levels of serological total IgG antibodies to OspC K over time 
following oral immunization of mice with E. coli expressing OspC K at different time 
points, before (days 28, 42 and 73) and after (days 105, 135 and 170) tick challenge, by 
ELISA (Figure 3-10). Production of total IgG antibodies to OspC K significantly 
increased due to a response to initial immunization (day 28), which kept increasing as a 
consequence of the first (day 42) and then the second (day 73) vaccine boosts. Tick 
challenge was performed at day 73, when total IgG antibodies to OspC K reached the 
highest level, compared to control group, p<0.0001. Although after tick challenge, the 
antibody levels dropped they continued to be significantly higher compared to the levels 
in control group, p<0.001, and remained constant showing no differences between days 
135 and 170. Interestingly, we found no increase in the antibody levels to OspC in the 
control group after four (day 105), eight (day 135) or thirteen weeks (day 170) after tick 
challenge. 
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CHAPTER 4.    DISCUSSION AND CONCLUDING REMARKS 
 
 
Discussion 
 
This study examined whether recombinant E. coli –based oral vaccines expressing 
OspC K, OspB and BBK32 from B. burgdorferi as well as Salp15 and Salp25 from 
Ixodes scapularis could induce a humoral antibody response that protects against 
infection with multiple strains of B. burgdorferi transmitted via tick bite. Our vaccine 
technology consisted of recombinant live E. coli expressing the leader sequence of B. 
burgdorferi OspA lipoprotein fused to the N-terminus of each candidate immunogen 
(OspC K, OspB, BBK32, Salp15 or Salp25), aiming to target them across the 
cytoplasmic membrane to the cell envelope as previously shown [110, 114, 115]. 
Analysis of localization and lipidation of the five vaccine constructs used in this study 
revealed that the OspA signal peptide tagged OspC K, OspB, BBK32, Salp15 and Salp25 
for translocation across the cytoplasmic membrane, given that these proteins were 
primarily found in the envelope fraction (>60%) as opposed to the cytosolic fraction of 
the cell. Furthermore, OspC K, BBK32 and Salp15 constructs partitioned mostly into the 
detergent phase (Figure 3-1), the hydrophobic fraction of the E. coli cell envelope, 
consistent with protein lipidation and with our previous findings [110, 114, 115]. 
 
Amongst all tested oral vaccine constructs, only mice immunized with E. coli 
expressing OspC K induced a significant systemic humoral antibody immune response as 
showed by serological IgG (Figure 3-2A) and mucosal IgA (Figure 3-4A) immune 
responses. Given that this oral construct was our most promising candidate, vaccine 
efficacy studies following oral immunization with E. coli expressing OspC K were 
further pursued. 
 
A multitude of studies have previously shown that OspC vaccination affords 
protection not only via needle infection [74, 77, 79] but also via tick challenge [69, 70] 
against B. burgdorferi strains with a single and a homologous OspC type. However, these 
conditions do not represent what happens in the natural setting. In nature, B. burgdorferi 
infection is acquired by tick bite that does not simply transmit a single OspC strain to the 
host, as reproduced by these experiments [69, 70, 74, 77, 79], but transmits 
simultaneously a mixture of heterologous strains of B. burgdorferi, including multiple 
OspC types [33, 55, 83, 116, 117]. Therefore, the aforementioned studies [69, 70, 74, 77, 
79] have failed to evaluate the potential of protection conferred by OspC vaccination in 
the natural context of infection, and thus their findings should not be taken as definitive 
evidence for OspC immunoprotection. In an effort to address this need, we next sought to 
investigate the ability of an OspC-based vaccine to confer protection upon co-infection 
with heterologous B. burgdorferi OspC populations after tick challenge. 
 
Intending to perform our OspC K vaccine efficacy studies using the natural route 
of B. burgdorferi transmission, we attempted to produce flat nymphs infected with 
multiple strains (MS) of B. burgdorferi, harboring multiple types of OspC, as well as flat 
nymphs infected with a single type of OspC, B. burgdorferi OspC type K (OspC K) 
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strain. We generated flat nymphs infected with multiple strains of B. burgdorferi, with an 
infection prevalence of 83% (Figure 3-5B). Despite the fact that all mice inoculated 
intradermally with B. burgdorferi OspC type K strain became infected (Figure 3-5A), we 
were not able to generate infected flat nymphs from larvae that fed on these mice, as 
shown by an infection prevalence of 0% (Figure 3-5B). One reason that might explain 
our results is that larval I. scapularis could not acquire B. burgdorferi OspC type K strain 
upon feeding. Another possibility is that larvae acquired spirochetes during feeding, but 
these were not able to survive in the engorged larvae and were, eventually, shed by the 
vector. Once acquired, spirochetes must adjust to the physiology of the arthropod and 
endure this new environment. Colonization, persistence and survival of B. burgdorferi in 
the tick are tightly regulated by differential gene expression [50, 122-125]. For example, 
spirochetes that fail to adhere to midgut tissue are unable to survive within the tick as 
early as 48 hours postfeeding [125]. Furthermore, production of laboratory-infected ticks 
using B. burgdorferi OspC type K strain is not described in the literature. In fact, in the 
natural context of B. burgdorferi transmission, ticks in the wild harbor multiple strains of 
B. burgdorferi, including multiple types of OspC and not single types [55, 83, 116, 117]. 
Therefore, it is tempting to speculate that the reason why we were not able to produce 
ticks infected with B. burgdorferi OspC type K strain was because this strain, although it 
efficiently infected mice by needle inoculation, might lack ecological fitness to be 
acquired and/or to persist within the tick, by itself. Yet, we cannot exclude the fact that 
this isolate was grown in vitro, a method prone to induce loss of plasmids in B. 
burgdorferi [126-129] that encode for genes required for the establishment and 
persistence of tick infection [124, 130, 131]. Persistence of B. burgdorferi in an unfed 
tick gut represents one of the most challenging stages of the spirochete lifecycle since the 
bacterium has to survive during prolonged periods of nutrient deprivation. As such, 
during this stage, the spirochetes adapt a dormant metabolic state that still remains poorly 
understood [132]. Therefore, despite speculation, further studies are needed to proper 
address our failure in generating flat nymphs infected with B. burgdorferi OspC type K 
strain.  
 
Vaccine efficacy of our OspC K oral construct was next assessed by challenge 
performed with laboratory-produced nymphs infected with multiple strains of B. 
burgdorferi. We found that upon challenge, similarly to controls, OspC K–immunized 
mice had spirochetal dissemination to their tissues (Figure 3-6) and developed IgG 
antibodies to the spirochete (Figure 3-7), showing that OspC K immunization did not 
prevent infection with multiple strains of B. burgdorferi via tick challenge.  
 
Induction of OspC on B. burgdorferi begins upon tick feeding [48, 49] and anti-
OspC antibodies have shown to be borreliacidal in mammals [133-135]. Although the 
role of OspC during tick transmission remains debatable [30, 51-53, 136], we 
investigated whether anti-OspC K total IgG antibodies present in the serum of OspC K-
immunized mice (Figure 3-2A) could have a borreliacidal effect within fed ticks. Upon 
analysis of engorged nymphs that fed on OspC K- immunized mice and on control mice, 
we found that there were no differences between the number of B. burgdorferi harbored 
in engorged nymphs that fed on OspC K-immunized mice and the number of B. 
burgdorferi harbored in engorged nymphs that fed on control mice (Figure 3-8). These 
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results indicate that antibodies to OspC in the serum of mice do not have a borreliacidal 
activity within the ticks upon blood meal intake, which is consistent with previous 
findings [69]. One could infer that a higher level of host serum OspC antibody might be 
necessary for protection. Still, this seems to be unlikely considering that at the day of the 
tick challenge (day 73), OspC K antibodies reached the highest level. In addition, 
between eight (day 135) and thirteen weeks (day 170) after the tick challenge, the 
antibody levels in the immunized mice remained constant and were still significantly 
higher when compared to the levels in control mice (Figure 3-10). Surprisingly, we did 
not detect any increase in the antibodies to OspC after tick challenge as shown by the 
levels in the control group (Figure 3-10). Yet, our observations support a recent study 
where only 13% of the dogs infected via tick bite developed IgM or IgG anti-OspC 
antibodies [137]. Antigenic variation of OspC does not seem to occur during infection 
[138, 139]. Therefore, the lack of an immunological response to OspC following 
infection with B. burgdorferi by tick challenge suggests that this protein is not being 
expressed on the spirochetes surface as they enter the host. In fact, B. burgdorferi is able 
to negatively regulate OspC expression in presence of anti-OspC antibodies as a 
mechanism of immune evasion [140-142]. Thus, if spirochetes do not express OspC on 
their surface shortly after they infect the host, the ability of circulating OspC antibodies 
to clear the pathogen is compromised. It is described that protective immunity to 
spirochetal infection can only be achieved if antigens are exposed on the spirochetal 
surface [143]. This could partially justify why our vaccine failed. 
 
More importantly, our findings showed that, despite significant levels of antigen-
specific antibodies (Figure 3-2A and Figure 3-4A), mice immunized with E. coli 
expressing OspC K were not protected from infection with a homologous Borrelia strain 
as shown by the presence of B. burgdorferi OspC type K strain in their tissues  
(Figure 3-9). This was consistent with a previous study where, despite the development 
of a strong humoral immune response, mice actively immunized with OspC isolated from 
B. burgdorferi strain N40 were not protected from infection via tick-borne challenge 
carrying that same (homologous) spirochetal strain [80].  
 
Here, we have demonstrated that an OspC-based vaccine did not protect from 
infection with multiple strains of B. burgdorferi via the natural route of infection. Most 
importantly, we have shown for the first time that an OspC K-based vaccine does not 
afford protection to the homologous B. burgdorferi OspC isolate (type K) if transmission 
occurs via ticks infected with a diversity of types of B. burgdorferi OspC strains. Our 
findings are both critical and relevant, and should be considered in future studies 
involving the design and development of OspC-based vaccines against Lyme Disease. 
 
 
Concluding Remarks 
 
B. burgdorferi undergoes dramatic adaptive changes in gene expression and 
protein composition to persist at different stages of the mouse-tick-mouse infectious 
cycle [123, 144]. The bacteria has the ability to regulate the expression of several 
lipoproteins in response to environmental cues such as changes in temperature [145], pH 
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[146] or cell density [147]. For example, as the spirochete migrates from the tick to the 
host, it differentially expresses lipoproteins. OspC is induced during tick feeding [30, 48, 
49, 51], and antibodies to OspC have been shown to protect mammals against infection 
with B. burgdorferi [69, 74, 77, 80]. Despite these attributes that make OspC a promising 
vaccine candidate, its function in mammalian infection has remained undefined. 
Moreover, discrepancies regarding the potential of OspC as a vaccinogen exist in the 
current literature [69, 70, 74, 76-80] and should be further elucidated. Aiming to expand 
our understanding of this antigen, it is pivotal that we revisit important literature findings, 
reassess their significance and integrate them in future studies of development and testing 
of OspC-based vaccines.  
 
It is described that B. burgdorferi shuts down ospC expression in a reversible 
manner in the presence of anti-OspC antibodies in the host [140-142]. Moreover, despite 
the fact that spirochetes up regulate OspC once the tick starts feeding [48, 49], they 
down-regulate OspC production while they move from the gut to the salivary glands and 
enter the host [30], and the ones that fail to repress OspC are unable to establish infection 
in mice [148]. Taken together, these findings suggest that the ability of B. burgdorferi to 
shut down ospC expression allows the pathogen to avoid clearance, and thus to succeed 
during mammalian infection and persist throughout its enzootic life cycle. It is tempting 
to speculate that, from an evolutionary standpoint, a population of spirochetes that retains 
this ability might be favorably selected in the natural setting. Wild ticks transmit, 
simultaneously, a mixture of heterologous strains of B. burgdorferi, including multiple 
OspC types [55, 83, 116, 117] to their host in nature. Not surprisingly, the coexistence of 
heterogeneous B. burgdorferi strains favors the maintenance of the organism in reservoir 
mammals in nature [117]. In addition, tick-transmitted and culture-grown spirochetes 
have shown to have different antigenic and genetic structure. For instance, immune sera 
protected mice challenged with B. burgdorferi cultured in vitro but did not protect them 
from infection if the same spirochete was tick-transmitted [149]. Despite this knowledge, 
the majority of studies that assessed protection conferred by vaccination with OspC used 
conditions that do not mimic the natural context of spirochete transmission, undervaluing 
the tick-spirochete interaction. Evaluation of efficacy of OspC-based vaccines by tick 
challenge is quite scarce [69, 70, 80], as most authors have been assessing vaccine 
efficacy using the non-natural route of B. burgdorferi infection [74, 76, 77, 79]. The few 
who tested their vaccines against tick challenge [69, 70, 80] used a single strain of B. 
burgdorferi, neglecting the fact that wild ticks are infected with and transmit multiple 
heterologous OspC strains to the host [33, 55, 83, 116, 117]. Familiar with these 
limitations, we designed a study where we applied our expertise in tick production and 
mimicked the natural route of B. burgdorferi infection, aiming to extend our current 
knowledge about OspC vaccine efficacy. 
 
Here, we developed and tested an immunogenic OspC-based oral vaccine in vivo 
against challenge with multiple strains of B. burgdorferi isolated from heart of 
Peromyscus leucopus, the natural reservoir host, infected with field caught ticks from 
endemic areas for Lyme Disease. We showed that, despite the development of a strong 
humoral response to OspC K, mice were not even protected from infection with the 
homologous type of B. burgdorferi (OspC type K) when the spirochete was presented to 
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the host in the natural context of transmission. Protective antibody responses can be 
circumvented by B. burgdorferi during natural transmission [149, 150]. For instance, 
immunization with B. burgdorferi lipoprotein decorin-binding protein A (DbpA) elicited 
a strong protective antibody response B. burgdorferi in mice. However, this protective 
response was only seen in mice that were challenged by needle inoculation with in vitro-
cultivated spirochetes [151]. When spirochetes were transmitted through I. scapularis 
bite this protective response was no longer apparent, which led the authors to hypothesize 
that antibodies to DbpA are unable to kill B. burgdorferi if the spirochete is transmitted 
by tick bite [150].  
 
Changes in B. burgdorferi gene expression during tick feeding are well described, 
they promote effective spirochete transmission and survival in the host [93, 123, 152], 
and should not be underestimated. Although far beyond our current understanding, one 
plausible explanation for our results is that if transmission occurs via tick bite, OspC is 
not shuttled to the surface of B. burgdorferi when the spirochete is being transmitted to 
the host. As a result, OspC was antibody-inaccessible in the host, which might have 
precluded specific antibodies from clearing the spirochete. It is described that OspC can 
be shuttled to and from the surface of the spirochete. OspC was barely detectable on the 
cell surface and it was mostly found in the periplasm of motile B. burgdorferi at different 
points during infection [153, 154].  
 
There is strong evidence that the antigenic composition of the Lyme Disease 
spirochete profoundly differs if the spirochete is tick-transmitted or culture-grown [132, 
149]. Reports where OspC conferred protective immunity are highly associated with 
challenges using in vitro cultivated spirochetes [74, 76, 77, 79], which led some authors 
to speculate that, under these conditions, the OspC antigen might be associated with a 
greater degree of surface exposure [153]. Interestingly, and along these lines, a study has 
shown that the majority of spirochetes (about 89%) present in the salivary glands of ticks 
that have fed on animals for more than 53 hours, a time period that coincides with the 
time required for infection of mammals, did not express OspC [30]. This suggests that if 
transmission of B. burgdorferi occurs via tick bite, only a minor population of OspC-
producing bacteria enters the host, which supports our results. It is possible that when B. 
burgdorferi is carried in wild ticks and co-exists with multiple and heterogeneous strains 
of OspC, the regulation, expression and surface localization of OspC within the 
spirochete are controlled by a complex cross-talk network, involving conditionally 
regulated and stochastic elements. This would favor spirochetal survival in the tick-borne 
parasites as well as evasion of the specific humoral immunity in the host. In addition, it 
would allow B. burgdorferi to preserve the integrity of the ospC gene during immune 
evasion [138] for subsequent need during its life cycle. Another reason that supports this 
hypothesis is that the temporal synthesis of OspC by spirochetes is involved exclusively 
in transmission from tick to mammal and not from mammal to tick [48]. Moreover, 
expression of OspC plays an essential part in the establishment of infection in a 
mammalian host [51, 52]. These findings suggest that the tick environment is solely 
responsible for modulation of OspC expression before B. burgdorferi is transmitted to the 
host, and therefore is imperative that OspC-based vaccines be tested via tick challenge. 
Failing to do so can have profound implications for vaccine testing and development. 
  53 
Despite a nearly complete absence of biosynthetic pathways [45], B. burgdorferi 
has an extraordinary zoonotic success, as it continues to be a public health threat [1, 4]. 
The transmission, survival and the pathogenicity of B. burgdorferi depend on the 
bacterium’s ability to adapt to markedly divergent conditions as it transits between the 
arthropod vector and the reservoir host. This requires a tightly orchestrated modulation of 
the bacterium transcriptome in response to different environmental signals [132], which 
can be largely explained by the co-evolution with its arthropod and mammalian hosts 
[25]. Yet, this intricate topic only recently began to be intensely investigated. 
 
Future studies should focus on further elucidating the interactions between the 
tick and B. burgdorferi as this would help in developing new and superior vaccination 
strategies to combat this arthropod-borne disease. We should start with tick challenges 
becoming the mainstay of Lyme Disease vaccine research. Furthermore, the identification 
of novel candidates for a second generation vaccine against Lyme Disease is of utmost 
importance and must focus on antigens produced within the tick at early stages of the 
blood meal that are important for spirochete transmission or vector colonization. 
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